

01-04-00

A

01/03/00
jc674 U.S. PTO

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent of: John D. Noti

Date: January 3, 2000

Docket No.: 052544-0108

jc584 U.S. PTO
09/476202
01/03/00

For: **MYELOID CELL PROMOTER AND CONSTRUCTS CONTAINING SAME**

CERTIFICATE OF MAILING

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, DC 20231


"Express Mail" Mailing Label No.: EL431001381US
Date of Deposit: January 3, 2000

I hereby certify that these attached documents

- * Patent Application
- * Twenty-five (25) pages of figures (informal)
- * Declaration and Power of Attorney

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 35 C.F.R. §1.10 on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, DC 20231.

Enclosed for filing please find the above-referenced document. Please indicate receipt of this document by returning the attached postcard with the official Patent and Trademark Office receipt stamped thereon.


Laura K. Weigt
Foley & Lardner
P. O. Box 1497
Madison, Wisconsin 53701-1497
(608) 257-5035

Inventor: John D. Noti

MYELOID CELL PROMOTER AND CONSTRUCTS CONTAINING SAME

5

TECHNICAL FIELD

The present invention relates to a novel promoter isolated from a myeloid cell, as well as *cis*-acting elements from the myeloid cell, and to novel constructs containing the same.

BACKGROUND OF THE INVENTION

10

The expression of foreign genes in various cell types has become a commonplace occurrence in the field of biotechnology. The expression of the foreign, or heterologous, gene is performed by the transcription of the genetic information in the gene from DNA to RNA. The RNA is then translated into the protein for which the gene encodes.

15

In transcription, the RNA is synthesized using the DNA of the gene for a template. The RNA is synthesized by a reaction catalyzed by RNA polymerases. The RNA polymerase binds to a particular molecular site on the DNA to initiate the transcription process. This site to which the RNA polymerase binds is known as the promoter.

20

Therefore, in order to express heterologous genes in foreign cells, the genes must be under the control of a promoter. Although numerous promoters for expressing foreign genes have been taught in the literature, these promoters have generally failed to function when used to express genes within myeloid cells. Therefore, a need exists for promoters which may be used to express genes within
25 such cells.

Integrins are a large family of cell surface glycoproteins that are heterodimers comprised of α and β chain subunits. The promoters of integrins are

of special interest as these promoters may be used to express genes in a myeloid-specific manner. This is especially useful, as typical promoters which are used in genetic research, such as retroviral promoters, become repressed after being introduced into myeloid cells.

5 Genes linked to myeloid specific promoters may be used in a wide variety of applications. These applications include use in the development of cancer vaccines, as well as being used for screening compounds for their effect on myeloid cell specific gene expression.

10 A need therefore remains for the identification and isolation of myeloid cell specific promoters.

SUMMARY OF THE INVENTION

The present invention relates to myeloid cell specific gene expression. The invention includes myeloid cell specific gene expression under the control of a myeloid cell specific promoter, preferably the CD11d promoter.

15 A preferred myeloid cell specific promoter is all or a functional portion of isolated or recombinant SEQ ID NO:1, such that the sequence is sufficient to direct myeloid cell specific expression of a gene. More preferably, the myeloid cell specific promoter of the present invention is the -946 to +74 region that is upstream (5') of the CD11d gene, as identified by SEQ ID NO:1. In
20 particular, the present invention relates to portions of this sequence that are sufficient to direct myeloid cell specific expression of a heterologous gene, and also includes modifications of this sequence that retain sufficient activity to direct myeloid cell specific expression of a heterologous gene. More preferably, the invention relates to the region from -173 to +74 that is upstream (5') of the CD11d
25 gene. The invention further includes all or a functional portion of isolated or recombinant SEQ ID NO:1, wherein the sequence comprises one or more modifications, such that the modified sequence retains sufficient activity to direct myeloid cell specific expression of a gene.

The invention further relates to a *cis*-acting element that influences the activity of the myeloid cell specific promoter. This influence may be either to increase or decrease the activity of the myeloid cell specific promoter. The *cis*-acting element comprises a portion of SEQ ID NO:1 that is sufficient to influence the activity of the myeloid cell specific promoter. In particular, the present invention relates to portions of this sequence that are sufficient to function as a *cis*-acting element that influences the activity of the myeloid cell specific promoter, and also includes modifications of this element that retain sufficient activity to influence the activity of the myeloid cell specific promoter.

A preferred *cis*-acting element is the -173 to +74 region that is upstream (5') of the CD11d gene as shown in SEQ ID NO:1. Also preferred is the -72 to -40 region, more specifically, the -63 to -40 region, that is upstream (5') of the CD11d gene. In particular, the invention is directed to *cis*-acting elements that positively influence the CD11d promoter, increasing the activity of the promoter.

Cis-acting elements that negatively influence the CD11d promoter are also incorporated as part of the present invention. Particularly, the present invention relates to the -591 to -378 region that is upstream (5') of the CD11d gene as shown in SEQ ID NO:1. This *cis*-acting element contains a cell-specific silencer element.

The invention also relates to the approximately 12 kb sequence that is upstream (5') of the CD11d gene as shown in SEQ ID NO:2. This sequence further comprises additional *cis*-acting elements which influence the activity of the myeloid cell promoter of the present invention.

Additionally, the invention includes constructs that contain DNA sequences sufficient to direct myeloid cell specific expression of a gene. These constructs comprise both the promoter of the present invention and a heterologous gene, whereby the expression of the heterologous gene is under the control of the myeloid cell specific promoter. The invention is also directed to constructs that contain one or more *cis*-acting elements of the present invention together with the promoter of the present invention, both linked to a heterologous gene, whereby the

expression of the heterologous gene is under the control of the myeloid cell specific promoter of the present invention, and the promoter is influenced by the *cis*-acting element(s) of the present invention.

5 The invention also includes cells that have been transfected with a construct of the present invention.

In addition, the present invention relates to methods of producing a selected heterologous gene product in a myeloid cell. These methods include introducing into the myeloid cell a heterologous gene under the control of a myeloid cell specific promoter, or a *cis*-acting element that influences the activity of the
10 myeloid cell specific promoter, or both. The invention also includes cells produced by the methods described herein.

The present invention also relates to a method for identifying factors that can regulate myeloid cell specific transcription.

Further, the invention relates to a method of expressing a selected
15 heterologous gene product in myeloid cells of an individual, i.e., gene therapy. According to this embodiment, cells produced by the methods described herein are introduced into an individual, wherein they express a heterologous gene under transcriptional control of a myeloid cell specific promoter or a *cis*-acting element that influences the activity of the cell specific myeloid promoter, or both.

20 The present invention provides a means of insuring that a selected product, such as a diagnostic, therapeutic or prophylactic substance, is expressed from a specific cell type, *in vivo*. Therefore, the present invention is useful, for example, for gene therapy or to drive the expression of antiviral agents, such as anti-HIV constructs. The present invention also provides novel promoters which
25 may used to produce cancer vaccines. The present method is also useful in research, for example, to test the effect of the specific expression of heterologous genes, such as oncogenes, in specific cell types. Cells of the present invention are also useful for screening compounds for their effect on myeloid cell specific gene expression.

Further objects, features and advantages of the invention will be apparent from the following detailed description when taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

5 FIG. 1 shows the DNA sequence of the CD11d 5'flanking region and exons 1-7 and shows the sequence analysis data for the -946 to +74 CD11d promoter region (SEQ ID No: 1). The complete sequence in lowercase for introns 1, 3 and 4, and the sequence at the intron-exon junctions for introns 2,5, 6 and 7 and their sizes are shown. Consensus gt/ag splice junctions are underlined.

10 Putative binding sites for transcription factors are underlined and indicated above the sequence. The transcriptional start site (+1), the ATG translational start site (boxed), and protein sequence are shown.

FIG. 2 depicts a CD11d restriction map and location of exons. The location of the translational stop codon (TGA) for CD11d is shown. The direction of transcription of CD11c and CD11d is indicated with arrows. CD11d exons 1-7 are depicted as thickened vertical lines below the location of restriction enzyme sites for *Eco*RI (E), *Hind*III (H), *Xba*I (X), *Sac*I (S), and *Bam*HI (B). The reference point for the scale in bp is the CD11d transcriptional start site assigned as +1.

15 FIG. 3 shows the determination of the transcriptional start site for the CD11d gene with a schematic summarizing the sequencing gel information for the results of the transcriptional assays.

FIG. 4 is a graph illustrating that PMA downregulates the CD11d promoter. CD11d promoter activity in PMA-stimulated cells is expressed relative to that in unstimulated cells after correction for differences in transfection efficiencies.

25 FIG. 5 is a graph illustrating that the effect of PMA on the CD11d promoter is cell specific. The extent of CD11d 5'-flanking sequence in each construct shown is indicated. Promoter activity of each construct is expressed as

X-fold increase in activity above the background activity conferred by the promoterless control plasmid pGL3-Basic after correction for differences in transfection efficiencies. Expression of CD11c-*luc* is shown for comparison. The mean luciferase activities +/- the standard deviations are indicated.

5 FIG. 6 is a set of graphs illustrating that the Sp1-binding site is essential for CD11d promoter activity. The mean luciferase activities +/- the standard deviations are indicated.

 FIG. 7 is a set of graphs showing the induction of the CD11d promoter with Sp1. The mean luciferase activities +/- the standard deviations are indicated.

10 FIG. 8 is a sequence schematic summarizing the results of gel analysis illustrating the loss of Sp1-binding *in vivo* in PMA-stimulated myeloid cells. The open and gray circles below the sequence refer to the guanidine residues on the non-coding strand.

15 FIG. 9 shows the DNA sequence of the approximately 11.5 kb region located upstream (5') of the region coding for CD11d, CD11d exons and introns 1-7 for CD11d (SEQ ID No: 2).

DETAILED DESCRIPTION OF THE INVENTION

The following defined terms are used throughout the application:

20 **Cis-acting element:** A term used to describe a component of a DNA sequence which influences the activity of the same or immediately adjacent DNA sequence. For example, the DNA sequences to which transcription factors bind within promoters are said to be *cis*-acting control elements as they effect the expression of the adjacent gene or gene on the same chromosome.

25 **CD11:** A family of four leukocyte-associated single chain molecules that consist of two polypeptide chains; the larger of these chains (α) is different for each member of the family and includes CD11a, CD11b, CD11c and CD11d; the smaller chain (β) is common to all four large chain molecules.

Construct: Recombinant DNA sequences, both linear and circular, that comprise a functional portion of the myeloid cell specific promoter and/or *cis*-acting element(s) together with DNA encoding a heterologous gene. The myeloid cell specific promoter and/or *cis*-acting element(s) are functionally linked to the
5 heterologous gene in the constructs described herein.

Functional portion: refers to DNA sequences which are of sufficient size and sequence to have a desired function. In the present application, the desired function is the ability to cause tissue specific expression of a heterologous gene, or the ability to influence the activity of a promoter of the present invention.

10 **Heterologous gene:** Genes or DNA sequences which are not normally present in the cell as obtained, or which are not ordinarily functionally associated with a myeloid cell specific promoter region in the cell as obtained, or which are not ordinarily functionally associated with a myeloid cell specific *cis*-acting element that influences the activity of the cell specific myeloid promoter in
15 the cell as obtained.

Hybridizes: A DNA hybridizes to a second DNA if the first DNA has sufficient nucleic acid sequence complementarily to the second DNA to allow the formation of base pairing and hydrogen bonding under standard DNA hybridization conditions between the two DNAs.

20 **Myeloid cell:** Includes monocytes, granulocytes, macrophages, mast cells, erythrocytes, dendritic cells and natural killer (NK) cells, and precursor cells in these cell lineages.

Myeloid cell specific promoter: A DNA sequence which functions as a transcriptional control element or elements and which directs the expression of
25 a gene which is expressed in myeloid cells and which is expressed at reduced efficiency or not at all in other cell types and can include all or a portion of a DNA sequence which functions as a transcriptional control element.

Substantially similar: Two sequences that have a substantial degree of DNA or RNA sequence homology to each other.

The present invention is based on the isolation of a myeloid cell specific promoter and the demonstration that this promoter directs myeloid specific expression of a heterologous gene in transfection assays *in vivo*, and that the promoter is not capable of directing expression of heterologous genes in cancer
5 cells. The particular myeloid cell specific promoter of the present invention is the CD11d promoter.

The CD11d promoter of the present invention is all or a functional portion of isolated or recombinant SEQ ID NO:1, such that the sequence is sufficient to direct myeloid cell specific expression of a gene.

10 It has been surprisingly and unexpectedly discovered that the -946 to +74 region of SEQ ID NO:1, as illustrated in FIG. 1., contains the promoter activity for the CD11d gene. More specifically, it has been surprisingly and unexpectedly discovered that the -173 to +74 region is sufficient to confer leukocyte-specific expression of a gene in myeloid cells, when the gene is a
15 heterologous gene, such as a luciferase reporter gene.

These sequences which have CD11d promoter activity may further be modified. These modifications may be obtained by mutation, deletion and/or addition of one or more nucleotides in relation to the native sequence. They can be introduced in particular in order to improve the promoter activity, to suppress a
20 transcription inhibiting region, to make a constitutive promoter regulatable or vice versa, to introduce a restriction site facilitating subsequent cloning steps, to eliminate the sequences which are not essential to the transcriptional activity, and the like. Such modifications may be made by any means well known in the art. See., Noti *et al.*, Molec. Cell. Biol. 16:2940-50 (1996) and Noti *et al.*, Molec.
25 Immunol. 33:115-127 (1996), for methodologies using PCR to create and/or modify sequences.

The modified sequences may be screened for activity to determine if they retain the CD11d promoter activity. Such screening methodologies are well known in the art, and are further described in the following Examples.

The present invention is further based on the discovery of one or more *cis*-acting elements present within SEQ ID NO:1 that influence the CD11d promoter activity. Specifically, it has been discovered that several *cis*-acting elements are present upstream (5') of the CD11d gene that influence the CD11d promoter. This influence may be either to increase or decrease the activity of the myeloid cell specific promoter. The *cis*-acting element comprises a portion of SEQ ID NO:1 that is sufficient to influence the activity of the myeloid cell specific promoter. In particular, the present invention relates to portions of this sequence that are sufficient to function as a *cis*-acting element that influences the activity of the myeloid cell specific promoter, and also includes modifications of this sequence that retain sufficient activity to influence the activity of the myeloid cell specific promoter. The modifications would be created and screened in manners similar to those used to identify the promoter modifications as previously described.

Introns are known in the art to often have regulatory sequences contained therein. The invention contained herein also comprises the discovery of introns 1-6 which are shown in FIG. 9 (SEQ ID NO:2). The regulatory sequences contained within these introns can be determined by means well known in the art.

A preferred *cis*-acting element is the -173 to +74 region that is upstream (5') of the CD11d gene as shown in SEQ ID NO:1. This *cis*-acting element regulates cell-specific downregulation of CD11d by 4-phorbol-12-myristate 13-acetate (PMA). Also preferred is the -72 to -40, more specifically, the -63 to -40 region that is upstream (5') of the CD11d gene. This *cis*-acting element binds the transcription factor Sp1. It has been found that purified Sp1 binds at the -63 to -40 region that is upstream (5') of the CD11d gene; whereas crude protein extract that contains Sp1 binds to a larger region, namely, the -72 to -40 region that is upstream (5') of the CD11d gene. It has been discovered that a functional Sp1 binding site is necessary for high levels of CD11d promoter activity. The presence of these *cis*-acting elements positively influence the CD11d promoter, increasing the activity of the promoter.

It has also been discovered that Sp3 also influences upregulation of the CD11d promoter. Binding of Sp3 occurs in the regions identified in FIG. 9 (SEQ ID NO:2).

5 *Cis*-acting elements that negatively influence the CD11d gene are also incorporated as part of the present invention. Most notably, it has been discovered that the -591 to -378 region of SEQ ID NO:1 contains a cell-specific silencer element. As described in the following Examples, evidence of a cell-specific silencer element within the -591 to -378 region that serves to downregulate CD11d expression in Jurkat and IM-9 cells was found.

10 Additional cell-specific *cis*-acting elements that lie upstream of -944 of SEQ ID NO:1 are also part of the present invention. These *cis*-acting sequences lie within the approximately 12.5 kb region described in SEQ ID NO:2. Determination of these *cis*-acting elements is performed as described in the following Examples, or by any other means well known in the art.

15 The myeloid cell specific promoter(s) and *cis*-acting element(s) of the present invention can be obtained from a naturally-occurring source, or they can be produced using any of a variety of techniques, such as genetic engineering or cloning methods, PCR amplification or other synthetic techniques well known in the art.

20 The CD11d promoter is a strong promoter of expression in myeloid cells. Therefore, in addition to cell specific expression, the CD11d promoter offers the advantage of high level of expression of a desired product in myeloid cells.

Further the invention includes an isolated nucleic acid strand that hybridizes to either a nucleic acid strand having the sequence listed above (SEQ ID
25 NO: 1) or its complement, and constructs containing such isolated nucleic acid strands.

Additionally, the invention includes constructs that contain DNA sequences sufficient to direct myeloid cell specific expression of a gene. These constructs include constructs comprising both the promoter of the present invention
30 and a heterologous gene, whereby the expression of the heterologous gene is under

the control of the myeloid cell specific promoter. These constructs are constructed by methods well known in the art, including those exemplified in the following Examples.

Accordingly, the present invention also extends to a construct
5 comprising a DNA sequence having CD11d promoter activity and/or *cis*-acting
element activity according to the invention and a gene of interest placed under its
control. It goes without saying that a construct according to the invention may
contain several genes of interest either within the framework of a multicistronic
construct (schematically represented by the "*cis*-acting element and/or promoter-
10 gene 1-gene 2 . . . " arrangement) in which the different genes are placed
downstream of the *cis*-acting element and/or the promoter according to the invention
and are separated from each other by appropriate sequences, such as the IRES (for
Internal Ribosome Entry Site) elements allowing the reinitiation of translation or
alternatively within the framework of a bidirectional construct ("gene 1-promoter-
15 gene 2") in which a *cis*-acting element and/or promoter according to the invention is
inserted between two genes of interest in order to control their expression
simultaneously.

For the purpose of the present invention, a gene of interest may be
derived from a eukaryotic or prokaryotic organism or from a virus. It can be
20 isolated by any conventional molecular biology technique or can be synthesized by
the chemical route.

Moreover, a gene of interest may encode a polypeptide of interest
corresponding to all or part of a protein as found in nature (native or truncated
protein). It may also be a chimeric protein, for example coming from the fusion of
25 polypeptides of diverse origins or from a mutant exhibiting improved and/or
modified biological properties. Such a mutant can be obtained by conventional
molecular biology techniques. Among the proteins or polypeptides of interest, there
may be mentioned by way of nonlimiting examples: cytokines and growth factors.

A construct according to the invention may, in addition, comprise
30 additional elements necessary for the expression of the gene of interest (intron

sequence, transcription terminator sequence and the like) or alternatively for its maintenance in the host cell considered. Such elements are known to persons skilled in the art.

The invention also includes cells that have been transfected with a
5 construct of the present invention. The cells are transfected by the constructs of the present invention by any means well known in the art, including electroporation as taught in the following Examples. Other well known methods of transfecting cells with constructs of the present invention include liposome-mediated transfections and CaPO_4 -mediated transfections.

10 A host cell to be transfected according to the present invention may be derived from cells which include, but are not limited to, myeloid cells - HL60, THP1 (both macrophage cells), dendritic cells, T cells (Jurkat, RH9 cells), and B cells (IM9, Burkitt Daudi cells).

The present invention further relates to a method of transfecting a
15 myeloid cell line which comprises contacting a suspension of the cells with a heterologous gene construct, and exposing the cells to electroporation. In one embodiment of the invention the heterologous gene construct is a plasmid. In the preferred embodiment, the plasmid is a luciferase vector, such as firefly luciferase driven by the early SV40 enhancer/promoter.

20 The present invention is based, in part, on the discovery of an efficient technique for transfecting myeloid cell lines, and the discovery that the human genomic region upstream of (5' of) the genomic region encoding CD11d comprises a sequence which contains a control element(s) which is capable of directing myeloid specific transcription of a heterologous gene in transfected
25 myeloid cells. This sequence is also capable of directing reduced, but good, expression of genes within T and B cells, and reduced expression of genes in epithelial cells.

The present invention further includes a method for identifying
factors which can regulate myeloid cell specific transcription. This method
30 comprises (a) obtaining a myeloid cell which contains (e.g., has been transfected

with, or is derived from a cell transfected with) a heterologous gene under the transcriptional control of a myeloid cell specific promoter (i.e., a myeloid cell promoter-heterologous gene construct); (b) contacting the cell containing the myeloid cell promoter-heterologous gene construct with a selected factor; and (c) 5 assaying for expression of the heterologous gene and comparing its expression in cells contacted with the factor with expression of the gene in cells not contacted with the factor, and thereby determining whether the expression pattern of the heterologous gene is altered in cells contacted with the factor as compared to that of cells which have not been contacted with the factor. The construct and transfected 10 cells are prepared as previously described. The assay is performed as described in the following examples.

Myeloid cell specific promoter-heterologous gene constructs, *cis*-acting element-heterologous gene constructs, or *cis*-acting element/myeloid cell specific promoter-heterologous gene constructs can be used to screen for and 15 identify regulators of cell specific transcription. For example, myeloid cells may be transfected with DNA constructs containing functional portions of a myeloid cell specific promoter or *cis*-acting elements and a heterologous gene in the presence of a variety of potential transcription factors; the ability of the transcription factors to alter the function of the promoter or the *cis*-acting element may then be tested by 20 assaying for alterations in expression of the heterologous gene.

The promoter(s) and *cis*-acting element(s) of the present invention may be used in a number of applications. These promoter(s) and *cis*-acting element(s) provide a means of insuring that a selected product, such as a diagnostic, therapeutic or prophylactic substance, is expressed from a myeloid cell type *in vivo*. 25 Therefore, the present invention is useful, for example, for gene therapy or to drive the expression of antiviral agents, such as anti-HIV constructs.

The present invention also provides novel promoters which may be used in the production of cancer vaccines.

The present method is also useful in research, for example, to test the effect of the specific expression of heterologous genes, such as oncogenes, in specific myeloid cell types.

Cells of the present invention are also useful for screening
5 compounds for their effect on myeloid cell specific gene expression.

This invention is illustrated further by the following nonlimiting Examples. All of the references listed in the application are intended to be incorporated by reference.

10 Example 1 – Methodologies and Materials For Identification of CD11d Promoter

The following methodologies and materials were used in the following Examples:

A. Cell Culture

The cell lines used were: THP-1 (acute monocytic leukemia, ATCC
15 TIB-202), HL60 (promyelocytic leukemia, ATCC CCL 240), IM-9 (B-cell multiple myeloma, ATCC CCL-159), Jurkat (T-cell acute leukemia, ATCC TIB 152), MCF-7 (breast adenocarcinoma, ATCC HTB-22) and Schneider's *Drosophila* 2 (D. Melanogaster embryo, ATCC CRL 1963). THP-1, HL60, and Jurkat cells were grown in RPMI-1640 medium containing 10% fetal calf serum (Biofluids,
20 Rockville, MD). IM-9 cells were grown in RPMI-1640 medium containing 20% fetal calf serum (Biofluids, Rockville, MD). HeLa and MCF-7 cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal calf serum (Biofluids, Rockville, MD). *Drosophila* Schneider 2 cells were grown in Schneider's medium containing 10% insect-tested fetal calf serum (Sigma, St. Louis, MO). All media
25 contained 100 U/ml of penicillin and 100 U/ml streptomycin.

B. Plasmids

A series of 5'-unidirectional deletions of the -946 to +74 region of the CD11d promoter were prepared by the polymerase chain reaction (PCR) with
30 oligonucleotide primers specific to this region and fused to the firefly luciferase

gene (*luc*) in plasmid pGL3-Basic (Promega Corp., Madison, WI). The forward and reverse primers used in the PCR contained XhoI and HindIII restriction sites, respectively, for cloning of the final PCR product into pGL3-Basic. The -500 to +93 region of the CD11a promoter, the -500 to +50 region of the CD11b promoter, and the -196 to +30 region of the CD11c promoter were prepared in a similar manner and ligated into pGL3-Basic by the methods of Noti *et al.* and Noti. Noti, J. D., *et al.*, Mol. Cell. Biol. 16:2940-2950 (1996); Noti, J. D., J. Biol. Chem. 272:24038-24045 (1997).

A primer containing a deletion of the Sp1-binding site (-63 to -40) was used in the PCR to construct reporter plasmid CD11d(-173/+74)(Δ -63/-40)-*luc*. The plasmid pPacSp1, which expresses Sp1 from the *Drosophila* actin promoter, and the control plasmid pPacO, containing only the *Drosophila* actin promoter, were additionally utilized. The construction of plasmids that express Sp2 and Sp3 from the actin promoter (plasmids pPacSp2 and pPacSp3, respectively) were prepared as described by Noti, J. D., J. Biol. Chem. 272:24038-24045 (1997). The integrity of all constructs was verified by DNA sequence analysis.

C. Transfections and Reporter Assays

Transfections of human cells were performed by electroporation as taught by Noti *et al.*, DNA and Cell Biol., 11:123-138 (1992). The transfected cells were analyzed with the Dual-Luciferase Reporter Assay System (Promega Corp., Madison, WI). Approximately 1×10^7 cells of each leukocyte line or 2×10^6 of MCF-7 cells were co-transfected with 15 μ g of each firefly luciferase reporter plasmid and 5 μ g of pRL-SV40 Vector (Promega Corp., Madison, WI). The pRL-SV40 vector contains *Renilla* luciferase driven by the early SV40 enhancer/promoter. This vector provided an internal control in which to normalize expression from each firefly luciferase reporter. Electroporated cells were transferred to tissue culture dishes containing 15 ml of medium, and, under certain conditions, phorbol 12-myristate 13-acetate (PMA, 10 ng/ml final concentration) was added one hour later. The cells were harvested 24 hr. post-transfection and

luciferase activity was assayed. Firefly luciferase light output was measured in a LB96V-2 Wallac Berthold plate luminometer and normalized against *Renilla* luciferase from the co-transfected vector or against the total protein concentration in the cellular extract. DNA was introduced into *Drosophila* cells by calcium phosphate-mediated transfection as taught by Noti *et al.*, Mol. Cell. Biol., 16:2940-2950 (1996). Approximately 3×10^6 *Drosophila* cells were transfected with 15 μ g of a specific luciferase reporter plasmid and 5 μ g of pPacSp1, pPacSp2, or pPacSp3. The total volume of the plasmid transfection mix was adjusted to 30 μ g with the empty cassette plasmid pPacO. The calcium phosphate-DNA precipitates were left on the cells for 48 hr. prior to harvesting and assaying for luciferase activity. Most transfections were performed in triplicate and repeated two to three times to ensure reproducibility. Statistical analysis was performed using Microsoft Excel (Microsoft Corp, Roselle, IL). Data from individual experiments were pooled and expressed as the mean \pm standard deviation (S.D.).

15

D. In Vitro DNase I Footprinting Analysis

The PCR was performed to prepare a double-stranded probe to the -173 to +74 region and one primer was labeled with [γ^{32} P]ATP. The probe was purified by electrophoresis through a 2% agarose gel on to NA45-DEAE paper according to the manufacturer's instructions (Schleicher and Schuell, Keene, NH). Approximately $1-2 \times 10^5$ cpm of probe (1-2 ng), and either 50 μ g crude nuclear extract protein (prepared according to Noti *et al.*, DNA and Cell Biol. 11:123-138 (1992)) or 1 to 4 footprinting unit (fpu, concentration determined by the manufacturer) (Promega Corp., Madison, WI) of purified Sp1 protein, were incubated in a total volume of 50 μ l binding buffer containing 0 or 5 μ g poly d(I-C), 6.25 mM $MgCl_2$, 50 mM KCl, 0.5 mM EDTA, 10% glycerol, 0.5 mM DTT, and 25 mM Tris-HCl, pH 8.0, for 15 min. at room temperature. Then 50 μ l of 5 mM $CaCl_2$ /10 mM $MgCl_2$, and 0.2-2 units of DNase I were added. After 1 min. at room temperature the reaction was stopped with 90 μ l of 0.2 M NaCl, 0.03 M EDTA,

1% SDS, 10 µg *Escherichia coli* tRNA, phenol\chloroform extracted, ethanol precipitated, and analyzed on a sequencing gel.

E. In Vivo Footprinting Analysis

- 5 The genomic DNAs from HL60, Jurkat, and IM-9 cells were purified from lysed cells by treatment with proteinase K followed by extensive phenol\chloroform extractions as taught by Mueller *et al.*, *In Current Protocols in Molecular Biology* (F.A. Ausubel *et al.*, eds.) pp. 15.5.1-15.5.26 (Greene Publishing and Wiley Interscience, NY) (1995). The genomic DNAs were treated
- 10 either *in vivo* or *in vitro* with dimethyl sulfate (DMS), cleaved with piperidine, and analyzed by ligation-mediated PCR as described by Noti *et al.*, *Mol. Cell. Biol.*, 16:2940-2950 (1996) and Mueller *et al.*, *In Current Protocols in Molecular Biology* (F.A. Ausubel *et al.*, eds.) pp. 15.5.1-15.5.26 (Greene Publishing and Wiley Interscience, NY) (1995). The unidirectional linker was composed of two
- 15 oligonucleotides,
- 5' GCGGTGATCCCGGGTGATCTGAAT 3' (SEQ ID NO:3) and 5' ATTCAGATCA 3' (SEQ ID NO:4). For footprinting the non-coding strand, the gene-specific primers corresponded to the following regions of the CD11d promoter: primer #1,
- 20 5' CTGGGAGAAGGAAGCCAGGTC 3' (SEQ ID NO:5) (for first strand synthesis from the denatured DNAs), which spanned the region -171 to -151; primer #2,
- 5' CAGGTTGTGGAGGGGGACAGAATGAGG 3' (SEQ ID NO:6) (amplification primer), which spanned the region -146 to -120; and primer #3,
- 25 5' GGTTGTGGAGGGGGACAGAATGAGGGTTTTTCC 3' (SEQ ID NO:7) (labeling primer), which spanned the region -144 to -112. First strand synthesis was done for 30 min. at 60°C. The DNAs were denatured for 4 min. at 95°C and amplified by the PCR (18 cycles) as follows: 1 min. at 95°C, 2 min. at 68°C, and 3 min. at 76°C. An extra 5 seconds was added to each extension step and
- 30 the final extension proceeded for 10 min. Two additional cycles of the PCR were

carried out to label the PCR products as follows: 1 min. at 95°C, 2 min. at 69°C, and 10 min. at 76°C. An approximately equal amount of each sample was loaded on a sequencing gel. The band intensities were analyzed on a Storm Phosphoimager.

5

F. RNase Protection, S1 Nuclease Analysis, and Primer Extension Analysis

The -381 to +74 region of CD11d was amplified by the PCR and cloned into the XhoI and HindIII sites of pGEM-7Zf(-) (Promega Corp., Madison, WI). This clone was linearized with XhoI, and used as template in an *in vitro* transcription system to prepare a 562 bp RNA probe (Riboprobe, Promega Corp., Madison, WI) that spanned this region according to the manufacturer's instructions. The RNA probe was labeled with [α -³²P]UTP to a specific activity of 7×10^7 cpm/ μ g, loaded on to a 5% polyacrylamide/8 M urea gel, and subsequently eluted into buffer containing 0.5 M ammonium acetate/1 mM EDTA/0.2% SDS.

10

15 Approximately $1-2 \times 10^5$ cpm of probe was annealed to either 20 μ g total RNA from HL60 or yeast cells and hybridized in 20 μ l of 80% deionized formamide/100 mM sodium citrate pH 6.4/300 mM sodium acetate pH 6.4/1mM EDTA for 16-18 hr. at 44°C. Following hybridization, the annealed probe/RNA complexes were treated with various concentrations of RNase A/T1 (Ambion, Inc., Austin, TX), extracted with proteinase K and phenol/chloroform, and analyzed on a 5% polyacrylamide/8 M urea gel.

20

For S1 nuclease analysis, a 247 nucleotide single-stranded DNA probe corresponding to the -173 to +74 region of CD11d was prepared by extension of a 22 nucleotide long primer on the luciferase reporter plasmid containing this region. The probe was end-labeled with [γ -³²P]ATP (probe specific activity of 5.3×10^7 cpm/ μ g). Hybridization of the DNA probe, prepared with the Prime-A-Probe Kit (Ambion, Inc., Austin, TX), to either 500 ng THP1 poly (A+) RNA or 20 μ g yeast total RNA and subsequent digestion with S1 nuclease was performed according to the instructions in the S1-Assay Kit provided by the manufacturer (Ambion Inc, Austin, TX). A second antisense DNA probe, 99

25

30

nucleotides long with the 5'-end positioned 19 bp upstream of the ATG codon, was chemically synthesized, end-labeled with [γ - 32 P]ATP (probe specific activity of 2.88×10^8 cpm/ μ g) and hybridized with HL60 poly (A+) RNA or yeast total RNA.

Primer extension analysis was performed essentially as described by
5 Noti *et al.*, DNA and Cell Biol., 11:123-138 (1992). 2.5 ng of a primer labeled with [γ - 32 P]ATP (specific activity of 1×10^9 cpm/ μ g) was hybridized to either 500 ng of HL60 poly (A+) RNA, 25 μ g HL60 total RNA, or 25 μ g yeast total RNA in 15 μ l of 150 mM KCl/10 mM Tris-Cl, pH 8.3 for 3 hr. at 50°C. Then, 30.5 μ l of a solution containing 29 mM Tris-Cl, pH 8.3 at 42°C/14.72 mM MgCl₂/8 mM
10 DTT/6.75 mg actinomycin D/0.2 mM each dATP, dTTP, dGTP, dCTP/20 units placental RNase inhibitor/2.5 units MuLV reverse transcriptase was added and incubation continued for 1 hr. at 42°C. The probe/RNA complexes were digested with RNase A/T1 (Ambion, Inc., Austin, TX), extracted with phenol/chloroform, and analyzed on a 5% polyacrylamide/8 M urea gel.

15

Example 2 - Isolation and Sequence Analysis of The CD11d 5' Flanking Region

The inventors isolated a genomic clone for CD11d that contains the intergenic region between CD11c and CD11d and the 5'-coding portion of CD11d. Utilizing this genomic clone, the regulatory mechanisms for CD11d expression were
20 determined and the clone analyzed in order to locate the CD11d promoter and *cis*-acting elements. CD11d is positioned no more than 11.5 kb downstream of CD11c.

A collection of CD11c positive cosmid clones was re-screened for the presence of CD11d. One clone was completely sequenced and contains exons 15-30 of CD11c, and exons 1-6 of CD11d. Exon 7 was located separately on another
25 clone. The genes were arranged in the same orientation, with the translational stop codon of CD11c positioned 11,461 bp upstream of the translational start codon of CD11d, as shown in FIG 2. The sequence of the 1.2 kb 5'-flanking region and exons 1-7 are shown in FIG. 1.

DNA sequence analysis of this clone showed that the ATG
30 translational codon for CD11d lies approximately 11,460 bp downstream of the

translational stop codon for CD11c and that both genes are transcribed in the same direction, as shown in FIG.2.

As illustrated in FIG. 1, the CD11d genomic clone was found to contain exons 1-7 not previously known in the art, which correspond to nucleotides 1-704 of the CD11d coding sequence. Exon 8 and possibly another exon is predicted to lie between nucleotides 704-982 of CD11d, which would be consistent with an average exon size of 100-150 nucleotides.

Example 3 - Determination of the Transcriptional Start Site of the CD11d Gene

10 Poly (A +) RNA and total RNA from myeloid HL60 cells was subjected to primer extension analysis with primers N379 (antisense primer with 5'-end positioned 20 nucleotides downstream of the ATG start site) and N470 (antisense primer with 5'-end positioned immediately upstream of the ATG start site), respectively. The longest extension product obtained with N379 was 101
15 nucleotides long, positioning the transcriptional start site 78 nucleotides upstream of the ATG site. Two extension products, 92, and 93 nucleotides long, were observed with N470 total RNA and would position the transcriptional start site(s) 14 and 15 bp further upstream. No extension products were detected when total yeast RNA was analyzed.

20 An S1 nuclease protection assay was performed with a 247 nucleotide single-stranded DNA probe that was generated by extension of [γ - 32 P]ATP-labeled N470 primer on a double-stranded DNA template with exonuclease-free Klenow polymerase. Hybridization of the probe with myeloid THP1 poly (A +) RNA and subsequent S1 nuclease digestion produced four major protected fragments 75-79
25 nucleotides long and with varying intensities. These results would, therefore, position the start of transcription 75-79 bp upstream of the ATG codon. No protected fragments were produced when the probe was hybridized to yeast total RNA. A second antisense DNA probe, 99 nucleotides long with the 5'-end positioned 19 nucleotides upstream of the ATG codon, was chemically synthesized,
30 end-labeled with [γ - 32 P]ATP and hybridized with HL60 poly (A +) RNA. S1

nuclease digestion produced four major protected fragments 49-52 nucleotides long, and the most intense fragment was 51 nucleotides long. This second S1 analysis positioned the start of transcription 69 bp upstream of the ATG codon. No protected fragments were produced when the probe was hybridized to yeast total
5 RNA.

An RNase protection assay was performed with a 562 nucleotide long RNA probe prepared by *in vitro* transcription and uniformly-labeled with [α - 32 P]UTP. The probe included the 455 nucleotides immediately upstream from the ATG codon. Hybridization of the RNA probe with total RNA from HL60 cells
10 and subsequent digestion with RNase A/T1 produced four protected fragments 71-74 nucleotides long. The length of the two most intense fragments would position the transcriptional start site 72 or 74 bp upstream from the ATG codon. No protected fragments were produced when the probe was hybridized to yeast total RNA.

15 Taken together, these results position two transcriptional start sites 69-79 bp and 91-92 bp upstream from the ATG codon. RNase protection assays, which provide for the most stringent hybridization and digestion conditions, and which were repeated five times, consistently confined transcription to within 71-74 bp upstream of the ATG codon. No TATA box is present, and transcription
20 is most probably determined by an initiator (Inr) control element which is found in the CD11a and CD11c genes. Since the 69 to 79 bp region shows homology to the classical Inr, and the largest RNase-protected fragment is 74 nucleotides long, we have assigned the thymidine 74 bp upstream from the ATG codon as the major site (+1) of CD11d transcription. FIG. 3 shows the determination of the transcriptional
25 start site for the CD11d gene with a schematic summarizing the sequencing gel information for the results of the transcriptional assays.

Example 4 - Functional Analysis of the CD11d Promoter

CD11d is expressed predominately on myeloid cells and exposure to
30 phorbol ester led to its downregulation from the cell surface. THP1 cells were

transfected with construct CD11d(-946/+74)-*luc*, which contains the -946 to +74 region of CD11d fused to the luciferase gene, and 24 hr. post-transfection were exposed to PMA for varying times, as shown in FIG. 4. Transfected THP1 cells exposed to PMA for up to 10 hr. showed no decrease in luciferase expression, however, after 24 hr., luciferase activity decreased 55%, as shown in FIG. 4. For comparison, expression of CD11a, which is detected in all leukocytes, and CD11c, which is predominately detected in myeloid cells, were monitored following transfection of the CD11a-*luc* and CD11c-*luc* constructs, respectively. Luciferase activity from CD11a-*luc* in THP1 cells was increased 4.5-fold, and luciferase activity from CD11c-*luc* was increased 8.3-fold in the presence of PMA, as illustrated in FIG. 4. These results show that chronic, rather than acute, exposure to PMA leads to downregulation of CD11d expression (and upregulation of CD11a and CD11c expression as expected), and that one or more *cis*-acting elements within the -946 to +74 region mediates this effect.

The -946 to +74 region was further examined to localize the *cis*-acting element(s) responsible for PMA-induced downregulation of CD11d and/or other elements that influence either basal or cell-specific expression. A series of CD11d reporter constructs containing progressively larger 5'-deletions was prepared and transfected into various cell lines. Luciferase expression from the constructs transfected into THP1 cells varied, but not significantly.

CD11d(-173/+74)-*luc*, which contains only the -173 to +74 region of CD11d, retained all of the activity obtained with CD11d(-946/+74)-*luc* and was 43-fold higher than that obtained with the promoterless pGL-3 Basic plasmid, as shown in FIG. 5A. In contrast, luciferase expression in MCF-7 breast cancer cells transfected with these constructs was increased only 2.5 to 6.4-fold over that obtained with pGL-3 Basic as shown in FIG. 5B. Expression from CD11d(-946/+74)-*luc* transfected into the B-cell line IM-9 was also reduced, as luciferase activity was only 8.1-fold over that obtained from pGL3-Basic, as illustrated in FIG. 5C. CD11d(-946/+74)-*luc* expression in the T-cell line Jurkat, was also reduced, although expression was higher than anticipated as it was 18-fold

greater than that obtained from pGL3-Basic, as shown in FIG. 5D. Deletion of the -591 to -378 region resulted in significant increases in luciferase expression in both IM-9 and Jurkat cells to approximately the level of expression of

CD11d(-173/+74)-*luc* in THP1 cells . See FIGS 5C and 5D, compare

- 5 CD11d(-591/+74)-*luc* with CD11d(-378/+74)-*luc*. This result indicates the presence of a cell-specific silencer. Luciferase expression from each of the CD11d-*luc* 5'-deletion constructs transfected into THP1 cells was reduced to approximately the same extent after exposure to PMA, as shown in FIG. 5A. A similar response to PMA was confirmed in another myeloid cell line, HL60, wherein it was discovered that PMA reduces expression in HL60 by 77%. This shows that a PMA-responsive *cis*-acting element(s) lies within the -173 to +74 region, since CD11d(-173/+74)-*luc*, which contains only this region, responds to PMA. In contrast, luciferase expression in IM-9 and Jurkat cells transfected with the CD11d-*luc* 5'-deletion constructs was not reduced by PMA, but instead, was increased 1.5 to 2.5-fold, see FIGS. 5C and 5D. Together, these results show two regions of CD11d that regulate its expression. The -591 to -378 region may contain a cell-specific silencer element, and the -173 to +74 region regulates cell-specific downregulation of CD11d by PMA .

20 Example 5 – Sp1 Binding to CD11d Promoter

- DNase I footprint analysis was performed to determine whether DNA binding proteins interact with the -173 to +74 region. When nuclear extracts prepared from unstimulated and PMA-stimulated THP1 cells were added to a probe labeled on the coding strand, strong protection of the -63 to -40 region was revealed. This same region was also protected by nuclear extracts prepared from unstimulated and PMA-stimulated Jurkat and IM-9 cells. When a probe labeled on the non-coding strand was used, strong protection of an overlapping region, -72 to -45, was detected with unstimulated and PMA-stimulated nuclear extracts from all three cell lines. DNA sequence analysis of the overlapping region revealed the presence of an Sp1 binding site.
- 30

In vitro DNase I footprint analysis showed that purified Sp1 protein could also protect the -63 to -40 region. Electrophoretic mobility shift analysis (EMSA) with THP1 nuclear extract protein and a probe to the -63 to -40 region revealed a protein/DNA complex that could be supershifted with anti-Sp1 antibody.

5

Example 6 – Sp1 Binding Region Required For CD11d Promoter Activity

To determine whether the Sp1-binding site is important for CD11d expression, this site was deleted from CD11d(-173/+74)-*luc* and its effect on expression was monitored in transfected cells. Deletion of the -63 to -40 region resulted in reduction of luciferase expression from CD11d(-173/+74)(Δ -63/-40)-*luc* to 24% in transfected THP1 cells, as shown in FIG. 6A. When transfected THP1 cells were exposed to PMA, expression from CD11d(-173/+74)-*luc* was reduced to 30%. Deletion of the -63 to -40 region further reduced luciferase expression from CD11d(-173/+74)(Δ -63/-40)-*luc* in PMA-stimulated THP1 cells only an additional 7%, as shown in FIG. 6A. Luciferase expression from CD11d(-173/+74)(Δ -63/-40)-*luc* in transfected IM-9 and Jurkat cells was similarly reduced to 20% and 24%, respectively, as illustrated by FIGS 6B and 6C. Although PMA did not reduce the expression of luciferase from CD11d(-173/+74)-*luc* transfected into IM-9 and Jurkat cells, expression from CD11d(-173/+74)(Δ -63/-40)-*luc* was reduced to 18% and 20%, respectively, as shown in FIGS. 6B and 6C. These results show that the -63 to -40 region is essential for CD11d promoter activity in both myeloid and non-myeloid cells. Further, the inability of PMA to reduce luciferase expression from CD11d(-173/+74)-*luc* in non-myeloid cells is dependent on the integrity of this region.

25

Example 7 – Sp1 Regulation of CD11d

To show that CD11d promoter activity is mediated through an interaction of Sp1 with the -63 to -40 region, *Drosophila* cells, which are deficient in Sp-related proteins, were cotransfected with pPacSp1 along with CD11d(-173/+74)-*luc*, as shown in FIG. 7.

30

The role of two other members of the Sp-family, Sp2 and Sp3, expressed from pPacSp2 and pPacSp3, respectively, was similarly analyzed. Sp1-dependent luciferase activity from the CD11d promoter was shown to increase 4.1-fold in *Drosophila* cells cotransfected with pPacSp1 and CD11d(-591/+74)-*luc*, as shown in FIG. 7A. In contrast, no induction of luciferase activity was seen when either pPacSp2 or pPacSp3 was cotransfected. Analysis of CD11d(-378/+75)-*luc* in cotransfection experiments yielded similar results.

For comparison, the response of the CD11c promoter to pPacSp1 and pPacSp3 is illustrated in FIG. 7B. As known in the art, CD11c promoter activity is dependent on both Sp1 and Sp3, and was indicated by the 19.5-fold and 18.9-fold induction by Sp1 and Sp3, respectively. It is also known in the art that Sp1 and Sp3 compete for the same sites on the CD11c promoter, however, luciferase activity from CD11d(-591/+74)-*luc* is maximal in the presence of pPacSp1 alone, and was not further increased when both pPacSp1 and pPacSp3 were present, as shown in FIG. 7A. Since pPacSp1-dependent expression of luciferase from CD11d(-591/+74)-*luc* is also not decreased in the presence of pPacSp3, Sp3 does not compete with Sp1 for binding to the same site. This suggests that Sp3 does not function as a repressor of CD11d promoter activity, in contrast to its reported repressor-like activity on other promoters.

Example 8 - Myeloid-Specific Downregulation of CD11d by PMA

The above results show that cell-specific downregulation of CD11d promoter activity is mediated through one or more *cis* elements within the -173 to +74 region. The inability of IM-9 and Jurkat cells to maintain CD11d expression in the presence of PMA when the Sp1-binding site was deleted indicated that Sp1 was a necessary factor involved in this response. Further, the possibility that loss of Sp1-binding was linked to downregulation of CD11d promoter activity in THP1 cells exposed to PMA was suggested when the reduction in luciferase activity from CD11d(-173/+74)-*luc* in transfected THP1 cells exposed to PMA was found to be about the same as that obtained in unstimulated THP1 cells transfected with the

Sp1-deleted construct CD11d(-173/+74)(Δ -63/-40)-*luc* (70% vs. 76% reduction, respectively, as shown in FIG. 6.

In vivo genomic footprinting was performed to determine if selective Sp1-binding occurs on the CD11d promoter. Genomic DNA, methylated *in vivo* with dimethyl sulfate, was isolated from HL60, IM-9, and Jurkat cells that were either unstimulated or PMA-stimulated. DNA was also isolated from HL60 and Jurkat cells, stripped of bound protein, and methylated *in vitro* as controls.

Analysis of the CD11d non-coding strand, as shown in FIG. 8, revealed hyposensitive sites in unstimulated HL60 DNA at positions -38, -40, -42, -43, -50, -52, -55, -56, -58 to -61, -63, -65, and -66 which correspond to guanine nucleotides in the Sp1-binding site. No protection was seen over these positions on genomic DNA from PMA-stimulated HL60 cells. In contrast, genomic DNAs from IM-9 and Jurkat cells, either unstimulated or PMA-stimulated, were similarly protected over these positions. From these results, we conclude that occupation of the CD11d promoter by Sp1 is significantly reduced in PMA-stimulated myeloid cells, and that myeloid-specific downregulation of CD11d expression is mediated through preferential loss of Sp1 binding following PMA stimulation.

It is understood that the invention is not confined to the particular embodiments set forth herein as illustrative, but embraces all such modified forms thereof as come within the scope of the following claims.

CLAIMS

What is claimed is:

1 1. A promoter of the CD11d gene comprising all or a functional
2 portion of isolated or recombinant SEQ ID NO:1, such that the sequence is
3 sufficient to direct myeloid cell specific expression of a gene.

1 2. The promoter of the CD11d gene according to claim 1,
2 wherein the functional portion is selected from the group consisting of -946 to +74
3 of SEQ ID NO:1, and -173 to +74 of SEQ ID NO:1.

1 3. The promoter of the CD11d gene according to claim 1,
2 wherein the sequence comprises one or more modifications, such that the modified
3 sequence retains sufficient activity to direct myeloid cell specific expression of a
4 gene.

1 4. The promoter of the CD11d gene according to claim 2,
2 wherein the sequence comprises one or more modifications, such that the modified
3 sequence retains sufficient activity to direct myeloid cell specific expression of a
4 gene.

1 5. A promoter of the CD11d gene comprising an isolated or
2 recombinant double-stranded DNA molecule wherein one of the strands hybridizes
3 to all or a functional portion of SEQ ID NO:1.

1 6. The promoter of the CD11d gene according to claim 5,
2 wherein one of the strands of the DNA hybridizes to all or a functional portion of a
3 sequence selected from the group consisting of -946 to +74 of SEQ ID NO:1, and
4 -173 to +74 of SEQ ID NO:1.

1 7. A *cis*-acting element that influences the activity of a myeloid
2 cell specific promoter, comprising a functional portion of isolated or recombinant
3 SEQ ID NO:1, such that the element is sufficient to influence the activity of a
4 myeloid cell specific promoter.

1 8. The *cis*-acting element according to claim 7, wherein the *cis*-
2 acting element is the -946 to +74 region of SEQ ID NO:1.

1 9. The *cis*-acting element according to claim 7, wherein the *cis*-
2 acting element is the -173 to +74 region of SEQ ID NO:1.

1 10. The *cis*-acting element according to claim 7, wherein the *cis*-
2 acting element is the -72 to -40 region of SEQ ID NO:1.

1 11. The *cis*-acting element according to claim 7, wherein the *cis*-
2 acting element comprises one or more modifications, such that the modified element
3 retains sufficient activity to enhance the activity of a myeloid cell specific promoter.

1 12. The *cis*-acting element according to claim 7, wherein the *cis*-
2 acting element is a binding site for a transcription factor.

1 13. The *cis*-acting element according to claim 12, wherein the *cis*-
2 acting element is a binding site for Sp1.

1 14. The *cis*-acting element according to claim 13, wherein the
2 binding site for Sp1 is the -63 to -40 (5') region of SEQ ID NO:1.

1 15. The *cis*-acting element according to claim 7, wherein the *cis*-
2 acting element is a myeloid cell specific silencer element.

1 16. The *cis*-acting element according to claim 15, wherein the *cis*-
2 acting element is the -591 to -378 region of SEQ ID NO:1.

1 17. A promoter of the CD11d gene comprising an isolated or
2 recombinant double-stranded DNA molecule wherein one strand hybridizes to all or
3 a functional portion of SEQ ID NO:1.

1 18. A cell specific CD11d promoter-heterologous gene construct,
2 the CD11d promoter comprising all or a functional portion of SEQ ID NO:1 such
3 that the sequence is sufficient to direct myeloid cell specific expression of a gene,
4 and a heterologous gene, wherein expression of the heterologous gene of the
5 construct is under transcriptional control of the CD11d promoter.

1 19. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 18, wherein the functional portion of the CD11d promoter is
3 selected from the group consisting of -946 to +74 of SEQ ID NO:1, and -173 to
4 +74 of SEQ ID NO:1.

1 20. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 18, wherein the Cd11d promoter sequence comprises one or
3 more modifications, such that the modified sequence retains sufficient activity to
4 direct myeloid cell specific expression of a gene.

1 21. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 18, wherein the construct further comprises a *cis*-acting element
3 that influences the activity of the CD11d promoter, the *cis*-acting element located
4 (5') upstream of the heterologous gene.

1 22. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 18, wherein the *cis*-acting element comprises a functional portion
3 of isolated or recombinant SEQ ID NO:1, such that the element is sufficient to
4 effect the activity of a myeloid cell specific promoter.

1 23. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 18, wherein the *cis*-acting element is the -946 to +74 region of
3 SEQ ID NO:1.

1 24. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 18, wherein the *cis*-acting element is the -173 to +74 region of
3 SEQ ID NO:1.

1 25. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 18, wherein the *cis*-acting element is the -72 to -40 region of
3 SEQ ID NO:1.

1 26. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 18, wherein the *cis*-acting element comprises one or more
3 modifications, such that the modified element retains sufficient activity to influence
4 the activity of a myeloid cell specific promoter.

1 27. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 18, wherein the *cis*-acting element is a binding site for a
3 transcription factor.

1 28. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 27, wherein the *cis*-acting element is a binding site for Sp1.

1 29. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 28, wherein the binding site for Sp1 is the -63 to -40 (5') region
3 of SEQ ID NO:1.

1 30. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 18, wherein the *cis*-acting element is a myeloid cell specific
3 silencer element.

1 31. The cell specific CD11d promoter-heterologous gene construct
2 according to claim 18, wherein the *cis*-acting element is the -591 to -378 region of
3 SEQ ID NO:1.

1 32. A myeloid cell that expresses a heterologous gene product
2 under transcriptional control of a CD11d promoter, wherein expression of the
3 heterologous gene of the construct is under transcriptional control of the CD11d
4 promoter.

1 33. The myeloid cell according to claim 32, wherein the CD11d
2 promoter comprises a double-stranded DNA molecule wherein one of strands has
3 the sequence which hybridizes to all or a functional portion of the DNA sequence of
4 SEQ ID NO:1.

1 34. The myeloid cell according to claim 32, wherein the CD11d
2 promoter is a functional portion of SEQ ID NO:1.

1 35. The myeloid cell according to claim 32, wherein the
2 functional portion is selected from the group consisting of -946 to +74 of SEQ ID
3 NO:1, and -173 to +74 of SEQ ID NO:1.

1 36. The myeloid cell according to claim 32, wherein the cell
2 further comprises a *cis*-acting element that affects the CD11d promoter.

1 37. The myeloid cell according to claim 36, wherein the *cis*-acting
2 element is the -946 to +74 region of SEQ ID NO:1.

1 38. The myeloid cell according to claim 36, wherein the *cis*-acting
2 element is the -173 to +74 region of SEQ ID NO:1.

1 39. The myeloid cell according to claim 23, wherein the *cis*-acting
2 element is the -72 to -40 region of SEQ ID NO:1.

1 40. A method of expression for myeloid cell specific genes,
2 comprising:

3 (a) positioning a gene of interest so that it is functionally
4 controlled by the promoter of claim 1; and

5 (b) expressing the gene of interest.

1 41. A method of expression for myeloid cell specific genes,
2 comprising:

- 3 (a) positioning a gene of interest so that it is functionally
4 controlled by the promoter of claim 2; and
5 (b) expressing the gene of interest.

1 ~~42.~~ A method for identifying regulating factors of myeloid cell
2 specific transcription, comprising:

- 3 (a) contacting a myeloid cell which contains a heterologous gene
4 under the transcriptional control of a CD11d promoter with a selected factor,
5 wherein the promoter comprises all or a functional portion of isolated or
6 recombinant SEQ ID NO:1, such that the sequence is sufficient to direct myeloid
7 cell specific expression of the heterologous gene; and
8 (b) assaying for expression of the heterologous gene and
9 comparing its expression in cells contacted with the factor with expression of the
10 gene in cells not contacted with the factor, and thereby determining whether the
11 expression pattern of the heterologous gene is altered in cells contacted with the
12 factor as compared to that of cells which have not been contacted with the factor.

1 ~~43.~~ A *cis*-acting element that influences the activity of a myeloid
2 cell specific promoter, comprising a functional portion of isolated or recombinant
3 SEQ ID NO:2, such that the element is sufficient to influence the activity of a
4 myeloid cell specific promoter.

ABSTRACT OF THE DISCLOSURE

MYELOID CELL PROMOTER AND CONSTRUCTS CONTAINING SAME

The present invention provides novel myeloid cell specific promoters,
5 and *cis*-acting elements that influence the activity of a myeloid cell specific
promoters, as well as promoter-heterologous gene constructs and transfected
myeloid cells which include the novel promoters and/or the novel *cis*-acting
elements. The present invention also provides a method of transfecting myeloid
cells and a method of producing a selected product within the transfected cells. The
10 invention also includes a method for identifying factors that can regulate myeloid
cell specific transcription.

FIGURE 1

TTTAATCATG GAATATTTC AACATACAGA AAAATCACAG AAAATAAATA ACAACCACTC ATTTATCTTC	-1101
TCCCAACCC CATGTAATAA ATATTAAAT ATTGTGTAA ATGCTAAAT TAACACATGC TAAAGGTTCC	-1031
TGGCTGGATG TGGTGGCTCA CGCCTGTAAT CCCAGTACTT TGGGAGGAGG AGGTGGGAGG ATTGCTTGAG	-961
TCCAGGAGCT CGAGACCAGC ATGGGCAACA TAGTGGGATC TCGTCTCTAC AAAAAACAAA AAAATTAGCT	-891
GGCATGGTG GTGTGCATCA GTAATCCAGC TGACTGGGAG GCTGAGGTGG GAGAAATTGCT TGAGTCTGGG	-821
AATTGAGGC TGCAGTGAGC CCTGATCATG CCAGTGCATT CCAGCATGGG CGACATAGCA AAACCTGTCA	-751
AAAAAAAAAA AGTTTCTCT TCTGCCCCAC CATAGACAAC CACTCTCTG ATTTCTATCT TCGTAGATGA	-681
API	
ATTTTGCCCA TTCTCTGTGA TATGAAAGGA ACCAGACATT AGGCATTCTG GTGTCTGGTT TCTTTCACIT	-611
AAGATAAAAT TGAGTTAACC TGTATTGTG TACAGAATG CAGTTTCTC TTGTTATTT ATTGTAAAGA	-541
CAGGTCTGG CTATGTTGCC TAGGCTGGTC TCGAATGTT GGCCTCAAGC AATCCACCTG CCAAGCTCTG	-471
GGACCACAG CATGAGCCAT GGCATCTGAT CAGTAGTTG ATCTTATTT TTGCTGAGTA GTAGCCCATG	-401
API	
GCATGACTTT ATTAFTTTGG GTGTCCATTC TCCTCTGGAG GGGCTCTGCT TTTTGAAACC ACACCTCTGG	-331
Ets	
CTAGCTCCCC TTCTCCCTGC CTCTCTGCAG GCTCACATCC ACATGCCAAG ACCTCTGCAG CCATTCTGCT	-261
Ets	
TCCTGTCTCTT CCATCTCTGT GGGACCTCAG AGAGCTACGG GGCTCCCTGG GTACCAACTG GCTCTCTGAG	-191
Sp1/Sp3	
CCCTGGGGGAG GGTGGTCTTC TGGGAGAAGG AAGCCAGGTC CCTGCAGGTT GTGGAGGGGG ACAGAATGAG	-121
Sp1/Sp3	
GGTTTTTCCC CAGGATGTG TTGGCCCTG CCCCCACTTC TGTTCATAA TTAACCCAGC CCCTCTCTACC	-51
Sp1/Sp3	
CACTGTGCCC CTCTTCCTGC TGTGTGGAG CCCTGAATCA TTATTTTAAAC TACCCCTGG GAGGGTGAGC	20
Ets	
ACCTCTCTG CTCTGTCCCC AACCTTCCAC TTCCCTCAAA CGCGCTGCTC AGGGATGACC TTCGGCACTG	90
M T F G T	
TGCTTCTTCT GAGTGtaag tggggccagg gtgctgggga gaagcttga ggagttctga ggggactcca	160
V L L L S	
tctgggaggg caggetgggg gctggtggtc ggtcccaacc actcttatga ggagctgagg caggggagtg	230
cttcagtgc gaggggcccg gagtgcagtag agtgtagcct gaatgaagag gggctcaggg gctgtgctca	300
ggtggcgact aagctacctc tccagctggc tatgtgtgctc cagggttccc tctcccact catggagttc	370
ctggtgtggg tgacagaggt ctcgccagcc tccccggga gtggaaggcc acagaagcca ccagggaggg	440
ggaaaggttg gacatcact cctggggcct nnnnttccc ccaagctctg actgcacgta ggggaagggc	510
INTRON 1	
ccccgtctga aaactgcac agagtcacat tcacgtgcca tcaaaaatca ggcttggtg ggtggggtg	580
ctcatgctta taatcccagc actttgggag gccgagatgg gcgtatcccc tgaggtcagg agtttgtgac	650
cagcctggcc aacatggtga aacccccatc ttacaaaaaa tataaaaatt agccgggcat ggtggcgtgc	720
acttgtaate ccagctactt gggaagctga ggcagagaaa tgccttgaac ccaggagacg gaagttgcag	790
tgagctgaga tctgtccgtt gcactccagc ctcagcaaca gaggcagact ccatctcaaa aaaaaaa	860
aaaaaagaa aaaaaagaaa aagaggctgg gaggctctag ggattggggc ttctttaact cccagcctcc	930
ccgcccacca aatattctc agTCTCTGCT TCTTATCATG GATTCACCT GCATGTGGAG GAGCCTACGA	1000
V L A S Y H G F N L D V E E P T	
TCTTCCAGGA GGATGCAGGC GGCTTTGGGC AGAGCGTGGT GCAGTTCGGT GGATCTCGgt agggcccaact	1070
I F Q E D A G G F G Q S V V Q F G G S R	
INTRON 2 (3019 bp)	
cccccaagt cccgtgtctc ccacccctcc tgtggtgca gtgacatggc catggttggt tctccagACT	4080
L	
CGTGGTGGGA GCACCCCTGG AGGTGGTGGC GGCCAACCAG ACGGACGGC TGTATGACTG CGCAGCTGCC	4150
V V G A P L E V V A A N Q T G R L Y D C A A A	
ACCGGCATGT GCCAGCCCAT CCCGCTGCAC Agtgagtgc cactgggaa ttggggccct caaccctct	4220
T G M C Q P I P L H INTRON 3	
ggacccaact gtgccccgc ttagettcca gtccagacct tcccgcgaaa tgagtgtgtg ctgtgagtga	4290
gacccccgt gtctgacct gcaTCCGCC CTGAGGCCGT GAACATGTCC TTGGCCCTGA CCTGGCAGC	4360
I R P E A V N M S L G L T L A A	
CTCCACCAAC GGCTCCCGGC TCCTGgtgag tgagtgtctt gggccacggg ggggtggggg gggggggggg	4430
S T N G S R L L INTRON 4	
gtgtgtgtgg ggaggaggt ggggtggga gtgaaggagg aggggtgct agggactcct gggtcacagy	4500
cttctgctc caoGCCTGTG GCCCGACCT GCACAGAGTC TGTGGGAGA ACTCATACTC AAAGGTTCC	
A C G P T L H R V C G E N S Y S K G S	
TGCTCTCTGC TGGGCTCGCG CTGGGAGATC ATCCAGACAG TCCCCGACGC CAGGCCAGgt aggtccctgg	4640
C L L L G S R W E I I Q T V P D A T P	
INTRON 5 (4267 bp)	
caggagctgc aggggggggt tggggcccg cagtgcact cagattctc cccattcccc cacaagAGTGT	8840
E C	
CCACATCAAG AGATGGACAT CGTCTTCTG ATTGACGCT CTGGAAGCAT TGACCAAAAT GACTTTAACC	8910
P H Q E M D I V F L I D G S G S I D Q N D F N	
AGATGAAGGG CTTTGTCCAA GCTGTCAATG CCACTTTGA GGGCACTGAC ACCCTGgtga agactgggca	8980
Q M K G F V Q A V M G Q F E G T D T L	
INTRON 6 (1255 bp)	
aacaatagta acaggcactg agccctgggc cctccccact ggcctttgca gTTTGCCTG ATGCACTACT	10240
F A L M Q Y	
CAAACCTCT GAAGATCCAC TTCACCTTCA CCAATTCCG GACCAGCCCG AGCCAGCAGA GCCTGGTGA	10310
S N L L K I H F T F T Q F R T S P S Q Q S L V D	
TCCCATCGTC CAAGTGAAG GCCTGACGTT CAGGCCACG GGCATCTGA CAGTGGTga aagcaacccc	10380
P I V Q L K G L T F T A T G I L T V	
gacccca.....INTRON 7	

FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9

Sequence Range: -11390 to 10387

Translational

stop
codon
for
CDHc

-11321
 TGATCCCTCT TTGCCTTGGA CTTCTTCTCC CGCGATTTTC CCCACTTACT TACCCTCACC TGTCAGGCTG
 -11251
 ACGGGGAGGA ACCACTGCAC CACCGAGAGA GGCTGGGATG GGCCTGCTTC CTGTCTTTGG GAGAAAACGT
 -11181
 CTTGCTTGGG AAGGGGCCTT TGTCTTGTC AAGTTCCAAC TGGAAACCCT TAGGACAGGG TCCCTGCTGT
 -11111
 GTTCCCCAAA AGGACTTGAC TTCGAATTTT TACCTAGAAA TACATGGACA ATACCCCCAG GCCTCAGTCT
 -11041
 CCCTTCTCCC ATGAGGCACG AATGATCTTT CTTTCCTTTC CTTTTTTTTT TTTTCTTTT CTTTTTTTTT
 -10971
 TTTTTTGAGA CGGAGTCTCG CTCTGTCACC CAGGCTGGAG TGAATGGCG TGATCTCGGC TCGCTGCAAC
 -10901
 CTCCGCCTCC CGGTTTCAAG TAATTCTGCT GTCTCAGCCT CCTGCGTAGC TGGGACTACA GGCACACGCC
 -10831
 ACCTCGCCCG GCCCGATCTT TCTAAAATAC AGTTCTGAAT ATGCTGCTCA TCCCCACCTG TCTTCAACAG
 -10761
 CTCCCCATTA CCCTCAGGAC AATGTCTGAA CTCTCCAGCT TCGCGTGAGA AGTCCCCTTC CATCCCAGAG
 -10691
 GGTGGGCTTC AGGGCGCACA GCATGAGAGC CTCTGTGCCC CCATCACCCCT CGTTTCCAGT GAATTAGTGT
 -10621
 CATGTCAGCA TCAGCTCAGG GCTTCATCGT GGGGCTCTCA GTTCCGATTC CCCAGGCTGA ATTGGGAGTG
 -10551
 AGATGCCTGC ATGCTGGGTT CTGCACAGCT GGCCTCCCGC GGTGGGTCA ACATTGCTGG CCTGGAAGGG
 -10481
 AGGAGCGCCC TCTAGGGAGG GACATGGCCC CGGTGCGGCT GCAGCTCACC AGCCCCAGGG GCAGAAGAGA
 -10411
 CCCAACCCT TCCTATTTTT TGAGGCTATG AATATAGTAC CTGAAAAAAT GCCAAGCACT AGATTATTTTT
 -10341
 TTTAAAAAGC GTACTTTAAA TGTGTGTGTT AATACACATT AAAACATGCA CAAAAAGATG CATCTACCGC
 -10271
 TCTTGGGAAA TATGTCAAAG GGTCTAAAAA TAAAAAGCC TTCTGTGGAT ATGAGTCCTG AAGGATGACA
 -10201
 CCCATGGGGT CCCTTTACCA CGGTGGACCC TGGCCAGCAC TGAGGCCTGG GGCCAGGACA AGAAGTTAAC
 -10131
 CAGAGTAGGG TTGTGAATAT CCCTCTCTTG GAAGTAACCT GACCTCTTAA TCTGCTCACT CCACTCTCAG
 -10061

GGCTGGTGCC GATGGTAAGC TGGTGGAGCT GTCGGGTGGA GGGGGCATAG AATAGAGAAG GGACAACCTC
-9991
CAGTGGCTAC TTTTCCACCT GGAAAGGTCT CTGGAGTGAC CAATACTCAC AAGCGTTTCC TACAAGTCCCT
-9921
AGGATGTGTT GAAGGGCACA CTGTCTGCAT ATAGTGAGTG ATTGAAGAAC ATGTTGGGGT CCCACATTGA
-9851
GAGCTGCTGC CCACAATAAG GTCATTCTTG CTATTATGCC ACCATCCTGG CATAAAGTTC ATCATGGTGC
-9781
TTGGCACTGA GCTGGGGGCC TCACAGGACA AGCCATTCCCT GACCTCGGAG TGACGCCACT GCAGCTATCA
-9711
CCAGCAAGGG ACCCGGGCCG TGTGGATGTT TCAATTAGAA AAACAGAAGG GAGGCAGTTG AGTGATTTTGA
-9641
AGGGAAGATG GAAAGTGGCC CTTTACCTCC AGCCAAAAAT GTCTGTCTTA TACATCAGCA GAGGCTCCAA
-9571
AATCCCTGTG GATTTTGAAG CTTTGTAGTC CCCAGGATGA CTAATTATTA TGCAGTTTCC TCAGAAAGGG
-9501
AATCAGAAGA TAAGGCTTTG TAAGAATTCA GCCCTAATGG CTGGGCACAG TGGCTCATGC CTGTAATCCC
-9431
AGCACTTTGG GAGGCCGAGG CAGGAGGATT GTTTGTGCTC AGAAATTGA GACCACCCTG GGTAAATATAT
-9361
TGAAACCTTG TGTCTACAAA AAAATTTAAA AATTACCCAG GCATGGTGCC ATGTGCTTGT AGTCCCAGCT
-9291
ACTTGGTAGG CTGAAGCAGG AGGATCACTT GAGCCTGGGA GGTGAGGAT ACAGTGAGCT GTGATTTGGA
-9221
CCACCACACT CCAGCCTGGG CAACAGAGAA AGATCATGTC TCAGAAAAAA AAAAAAAAT TGACCCTAGA
-9151
GTGGTGTTTC TCAAAATGTG TTCCACGAAC CACTGGTGGT CAATGATGGT CTTCTAAGTG GAAGGTTTTA
-9081
GAGAAAAAGA GCAAGAAACC CATACTCTC AAACATTTGA AACTAGTGAT TTGCACAGAA ATAGTGTTGT
-9011
GGCCTTAATA ATTGTGTGGC ACACGGACTC CAGGGACTAC AGTGGGTCTT TGTCTAAATT CAGGCAACAA
-8941
GTTGTTATTT TCTATTTTAT TTTATTATTA TTATTTTTTG AGATAGTCTC ACTTTGTCTC CCGGGCTGGA
-8871
GTGTAGTGGC ACGATCTCGG CTCAACGCAA CCTCTGTCTC CTGGGTTCAG GTGATGCCTC TGCCTCAGCC
-8801
TCCCAAGTAG CTGGGAGTAC AGGGGCGTAC CACCATGCCC ATTTTATTTT ATTTATTTTTT GAGACAGAGT
-8731

CTCGCTCTGT CACCCAGGCT GGAGTGCAGT GGCATGATCT TGGCTCACTG CAACCTCCGC CTCCCAGGTT
-8661
CAAGTTCAAG CGATTCTCCT GCCTCAGCCT CTGGAGTAGC TGGGATTACA GGCAGGCACC ACCATTTCCTA
-8591
GCTAATTTTT GTATTTTTAG TATAGATGGG GTTTCACCAT GTTGACTAGG CTGGTCTCGA ACTCCTGACC
-8521
TCATGATCCG CCTCCTCGG CCTCCGAAAG TGCTGGGATT AGAGGTATGA GCCACTGTAC TTGGCCGACA
-8451
AGGTGTTATT TTCTGATATT CTCCTTTGT GTGTTATTGT GTACATTTGT TACATTTGCA TTTTCAGGCT
-8381
TGGCTATTGT GTTGCATTAG ATCCCCGAAT CACAAAATGG ATCAATGGCT CAAAAGCATG GAAGTTGTGA
-8311
TTAAAACTA ATCTAATTGC TACAATTTAC AATAATGTCA TCAAAGTCAA TATTGACTTT TAAATATTGA
-8241
GCCCAGTGCA CGTATAGTAT AGACATGCAT ACCGGAATAA GTGATTGTGA GCCAAAACCC GAAAATATCT
-8171
AGAAGGTATT ATACTCCCTG ACAGGTAGGT TGTATTGGTT CTGACATGTA TTTGTCCCTA GTGTGCTGCC
-8101
CATTCTGAAA CTTTATCAAA CAGTCGCATG AACCTCTGAA AGCTTTTGTG TTATTTTCTT ATTTATTTAT
-8031
TTATTGAGAT GGAGTCTTGC TCTGTCGCCC AGGCTGGAGT GCAGTGGCAT CATCTTGGCT CACTGCAACC
-7961
TTTGCTCCT GGGTTCAAGT GATTCTCCTG CCTCAGCCTC TTGAGTAGCT GGGATTACAG GCGCGCACCA
-7891
CCACGCCAG CTAATTTTTG TATTTTLAGT ATAGACGGGG GTTTCACCAT GTTGGTCAGG CTGGTCTCGA
-7821
ACCCCTGACC TCATGATCTG CCTGCCTCAG GTAAAGCAAT AGAGATTCTT AGAACAACCTG CTACATGTAG
-7751
CTTTCCTATT CAAAAGTGAT TAGTGTTGTC ACCGAATACA GAGGAGACAG CAAAACCACA GTGACATAAA
~~7541~~ 7590 ~~7681~~
TCAAAGGTGC TTTTAAAGT AGCAAAAGTA GGTACAAGTC ACATAATTTT CAAGAAGCTT GTAGAAATGG
-7701
-7611
CAGTAGAGTT CATACTGCT ATTGAAAGGT TGCTTTTGGC TGCAAATAAT AGAAAAAAC AAAAGCATGT
-7541
AAGAGCAGAC AGAAGACCTT TACTCTGCAA GAGGTTTCAGG TGCAGGTTAG TGTTAATGC AGAGTCTCAG
-7471
CATTGACAGA TTCTTTCTGA TCTTCCAATT GATCGTCTT GCGGGGGCGG TTTAGTTCTT TCCCCTGAC
-7401

TAGGATTGGG TCAAATTCCA TCCCCTTGGT TGCATGCACT GCTGAGAAGG TGAGCATGTG CTTTTACAG
 -7331
 GCTTAATAAA AAGAGGTAGC TCCAGCCAGG TGCAGTGACT CATGCCTATA ATCTCAGCAC TTTGGGAGGC
 -7261
 AGAGGTGGGT AGGTCACCTG AGGTCAGGAG ATTGAGAACC AGCCTGACCA ACATGGCAAA ACTCTGTCTC
 -7191
 TACCGAAAAT ACAAAAATTA GCTGGGCATG GTGGCAGGTG CCTGTAATCC CAGCTACTTG GGAGGCTGAG
 -7121
 GCAGGAGAAT CGCTTGAACC TGAGAGGTGG AAGTTACAGT GAGCTGAGGT CATGCCACTT GCACTCCAGC
 -7051
 CTGGGGGACA GAGTAGAACT CTGTCTCAAC AAAAAAAAAA AAAAAAAGAG AAAAAAAG GAGGGTAGCT
 -6981
 CCACCAGCCA GGAAGGTGGC AGCGCTGGTG GCTGTTGGAT AGGCTACCTA CAGTGTCTGG CAAATACTAT
 -6911
 GCTTGAAGAC TATGCTGTGA GCAAGATTCC TTTGTGAAG AACAGCTTGG ACATTGTGTA TGTGAGAGGT
 -6841
 ATACAGCAGA ATAGCAGTGA CTAACGCTTG TGTGGGAGAG CAAGCATGTC ACCTCATACT TGGAAATACT
 -6771
 CACTGCCATA CAAAGTCTGA ATCAGCTTTC GTCTTTGTGC AACACATGTA TGTGGGAGCT TTTCAGCTGC
 -6701
 TGAAACCTCT AGTGACAGAA AAGGAGGTTT TGTGTTCAT TTGTAATTAA TGTTAATCCT ATGAGTGGTG
 -6631
 GGAGAGATAG TGAGGTAGGA GATCAGCAGG ACCTGTTTTT TGGTCACAAC CCAGCTAATC AGAGCATGAT
 -6561
 CTGGTCAAGA TGGGATGCAC TAAAAAACA GCCCAAACCA GCAGATGGCC AGGAAAGCAA ACTCTCATT
 -6491
 CCCTCGCCAC TTATTAGCAT AAAGACACTC CCACCGGTGC CATGACAGTT TACAAATGCC ATGGAAACAC
 -6421
 ACCATAGCAA CGGTCAGCAA GTTACCTCAT ATGGTTCTGG AACTCCCCA CACCTTTTCC AGATAGTTCT
 -6351
 GAATAACCCA CCCCTTAATT TGCATGTAAT TAAAAGTCGG TATAAGTACA GTTAGCCAGC AGCCCACTGG
 -6281
 CTGCTACTGT GGGCTCACTG CCTATGGGTT GTCTGTCTCT GCAAGGAACA GCTACCTTGC TGCCACTGCT
 -6211
 GCTTCAATAA ACCTGCTTTC TTCCACCACA GGCTCGCTCT TCAGTTCTTT CCTGAGCAAA GTTAAGAACC
 -6141
 CTCCCGGGCT AAGCCCCAAT TTTGGAGCTT GCCTGCCCTG CATCAGTAGA ATGGGCTAAC TACTTACGGT
 -6071

GCACTCAGGC TAAAGAGGCT GATGCTTGCA GGGCAGTATT CACAGAGCAC ACGGTAGTTC ACGGGATGCC
 -6001
 TCTCACCCCTT GACTCAGTGC TTAAGAAAGG AGGGAAAATG GTGAACATGA TCAAATCATG GCCATTGCCT
 -5931
 ATTCATCTTT TCAGTGTTGT ATGGAGGAAT AGGCAAGTAG GAGATTGCTT TTCACATTAA TGTCAAAGAG
 -5861
 AAAGATAGTT ACTTGGAAC TAAAAAATT AATTGTGATA AAATATACAT AACATAAAAT TTACCATCTT
 -5791
 AACCATTTTT AAGTATAGCC AATCTCAAGA GCTCTTTCTA TCTTGTAATA CTGAAACCCT ATACCCATTA
 -5721
 AACAACTCCC AATTCTCCCC TTTCCCTAAC TCCTGGCAAC CACAATTCTT TCTGTCTCTA TGAATTTGAC
 -5651
 TGCTTTGGCA TGTCATAGAA ATAGACTCAT ACAGCATTTG TCTTTTTGCG ACTGGCATAT TTTGCTTAGC
 -5581
 ATAATGTCCT CAAGGTTTAC CCATGTGCTA GCATGTGTCA GAATTCCTCT CCTTTTGAAG GCTGAATAAT
 -5511
 ATTCCATTGT GTGTATATAC CACGTTTTGT TTATCCATTT GCCCATCAAT GGGCATTTGG GTTGCTTTTT
 -5441
 TTGCCTCTCA TGAATGATGA ATATGGGCGC ACAAATATCT CTCAAGACC ATGCTTTCAA TTCTCTGGG
 -5371
 TATACACCCA GAAGTGGAAT TGCTGAATCA TATGGTAATT TTTTTTTTTT TTTGAGACAG AATCTTGCTC
 -5301
 TGTGCCCCAG GCTGGAGTGC AGTGGCACAA TCAGAGCTCA CTGCAGCCTT GGTCTTCTGG GCTCAAGCGA
 -5231
 TCCTCTTGCT TCAGCCTTCC GAGCTTCTGG GACTAAAGGT GTGTGCCATC ATGCCTGGCT AATGTTTTAA
 -5161
 AAACGTTGCC AGGCATGGTG GCTCGTGCTT GTAATCCTAG CACTTTGGGA AGCTGAGGCA GGTGGATCCC
 -5091
 CTGAGGTCAG GAGTTTGAGA CCAGCCTTGC CAACATGGTG AAATCCCGCC TGTACTAAAA ATACAAAAAT
 -5021
 TAGCTGGGTG TGGTGGCATG TGCCTGTAGT TCCAGCTACA GGCAGGAGAA TTGCTGGAAC CTGGGTGGCA
 -4951
 GAGGCTGCAG TGAGCCGAGA TTGCACCACT GCACTCCAGC CTGAGTGACA GAGTGAGACT CTGTCTCAAA
 -4881
 AAAAAAAAAA ATTTTAGAGA TGGTGTCTCA CTGTGTTGCC CAGGCTGGTC TTGAACTCCT GCCCTAAAGT
 -4811
 GATCCTCCTG CTTCCGCCTC CCAAAGTGCT GGGATTACAG GCATTAGCCA CCATGCCTGG CCTAGCTAAA
 -4741

TTGTCTTTAA TGTCGCATGT CTGCAAAAAA CACATCTATA AAGCTAGAAA AGTTGAGCAT CCAACTTTTT
 -4671
 ATGATTTAAC TCTCATGACC TGGCAATTTT TCTAGCAAGG AGCCTGGGCT GGTGGTTTTA GGAGAACTGA
 -4601
 GTGAAAAAAA GAAATACATT AACTAGATTG GATGCAAAGT GCCTGCTGGT CATGGGTGTT TTCTGCTGGC
 -4531
 CCCTGTTTCAT CTGTGCCTGT TAGCCCACCC ATGGGTGAGT GGGGCAAAGT GGCCAAACTG ATTCTTAAGA
 -4461
 GAGGCATACA TGCAGAATCC AAGTTAGTCA TGATTTCTGTT TCTAGTCTGA GTGAATGTGT GTCCAGAATA
 -4391
 TTTTATAAAC TTTATCAGCT CAGAGGGGAA AACCTGTCTC CATACTACGT GGTTTATACA AAGCTGTCAG
 -4321
 GAATTCAGCA TGATGAAGAA ATGCACAAAA CAAGTGTGAA CAGATAAGTA AAAGGATCTA CTGAAAATCT
 -4251
 TCAGGGTAGT ATATTGTGTG ACAGGACCAA GAATTTGAAG TCAACATCTG TATTTGTGCC CTCTGGACAA
 -4181
 AGGTATTATC CCTGATGATA TAAAAATTAA TTTTGGGCTG GGTGTGGTGG CTCATGCCTG TAATCCCAGC
 -4111
 ACTTTGGGAG GCTGAGGAGG GTGAATCGAC TGACGTCAGG AGTTGGAGGC CAGCCTGTAT CGACTAATAA
 -4041
 TACAAAAAAA TTAGCTGGAC ATGGTGGCGT GCACCTGTAA TCCCAGCTAC TCAGGAGGCT GAGGTGGGAG
 -3971
 AATTGCTTGA ACTCGGGAGG CCGAGGTTGC AGTGAGTCGC ACCACTGCAC TCTAGCCTGG GCGACAGAGT
 -3901
 GAGACWCCGT CTCAAAATAA ACAAATTAA TTTCGAGGCC AGGTGCAGTG GCTCCAGGTG CGGTGGTTCA
 -3831
 TACCTGTAAT TCCAGTGCTT TAGGAGGCCA GAGGATTGCT TGAACCCAAC AGTTCGAGAT CAACCTGGGC
 -3761
 AACATCAGTG AGACTCCATC TGTAAGAAAC AATCAAACAG ACAACAACA ACAACAAAA AACCAGAGGT
 -3691
 GGGAGGATCA CTTGAGCCCA GGAGTCCGAG GCTGCAGTGA GCTATGGTCA CGCCACTGCC CTCTAGCTTG
 -3621
 GGCAACAGTG CCAGACTCTG TCCTTAACAA CAACAACAAC AAAAATTAAT TCTACTTTAA CTGTCAGTTT
 -3551
 CATGATATCC TTCTATTAAG AAAAACCTTT TCTATCTGAT GAACTATTGG CTAGGTTTTT TTTCTCTCTG
 -3481
 CTTTTGACTA ATGCATTTAA TTACTTTCAT TTGCAAACTC TATCCTTCTC ATCAACTTTG TATTTTAGAT
 -3411

N489

-4494

N788

-383

GTGTCTATTG ACAGCCTGGC TTCCCTCAGC GATCATTATG ATGATCAAAG TAGATGAATA GGTAAAATTC
 -3341
 AATGCAAATA TTCCAGGGCA TCTAAATCCA TACCCCAAAT GGGAAAAGGG GAGAATTGGA AGCCAGCAAT
 -3271
 TTGAACACAT TACTATGGAT GTATTTTCT CATGCGGGG AAAAAGTGAT TTGGAGAGAG AGAATTATGA
 -3201
 ATGCATGTGA AGAATAAAGC CAAATTCCT GGGAGGAGGG GAAGACCAGG AGAAACAAAA CCAAATCCTG
 -3131
 GCTGTGGCCT CTAAGGCATG GGGACCTGGA GTTATGCTCT CCAGGCAGAC ACAGCTCATT CTGGAGAAAG
 -3061
 GCTGCAAAAA TATTCTCCTT CACATTGATT TGAAAAAAT TATTAAATTC TTGTTTTCTT ATTTATCTAA
 -3013 N487
 GTGTAACCTT TAAAACTTA CTGAGAGAAG ACGGGCACGG TGGCTCACTG CTGTAATCCA GTACTTTGGG
 -2991
 AAGTCAAGGC AGGTGGATCA CCTATGGTCA GGAGTTCGAG ACCAGCCTGG CCAATATGGC AAAACCCCGT
 -2921
 CTCTACTAAA AATACAAAAA TTATCAGGTG TGGTGGTGTG TGCCTGTAAT CCCAGCTACT CGGGAGGCTC
 -2851
 AGACAGGAGA ATCACTTGAA CCTGGGAGGC AGAGGTTGCA ATGAGCTGAG ATTGCACCAC TGCACTCCAG
 -2781
 CCTGGGCGAC AGAGCAGGAC TCCATCTCAA AATAAAAAATT AATTGATTAA TTAATTAAAA ATTTACTGAG
 -2711
 AGCTGGTGGT TCCTTTAAGG GTGGAGCCGC CATCAAGTCC CCAGAGGATG CCCTGAATTT GGGGGCATCA
 -2641
 CCTTCAGCTG CTGTGCACTC TGAGCCTTGG CAGCTCCAGC TCCAGGCCTG GGAGAAAGAT GATTTCTTGG
 -2571
 CAGCGTGCAG TGATTGTGAG CATTTGACTA CCTTACTGCA TTTTGCCCTT ATCAKTGCTC TCCAAACATG
 -2501
 AGTGGAAC AACAAAAATTT GCTGAGACAA GCGATAATAC GAGTTAGGGA AAGTTGGAGA ATTTTATAGT
 -2431
 TGCTGATATC AGCAAATCGT GAGTTTCAAG CACTAACTTA CAGAAGGAAG TCCAAAATTA AAGGGGATAT
 -2361
 AGAAATGTGT AAAAGATGAG GTGTGGTGAA GATGGAGAAA ATGAAGAGCT CTTTAAATTT CTGAATTATG
 -2291
 AAGAATCACC AACAAATTAT TTTGTGGTTC CAAATACAGG GAGAAGTTCA CAGATCCACA GAACTGATGA
 -2221
 CAGGGTGCAG CCAGCCACAA ACCTTTCAGC ACAAGAGGGA GAAGGCTGCC GCTCCACTTT GCCTGGGCAG
 -2151
 -2081

TCTTTGTAAG GCAGTAGATA AGTCAGCCTC GAAGTTAGCA ATCACAGCCC TCGGCTCGGT TTCCTGCAAG
GGCATCGTTA ATGCATCACA ATTAATTTCT TCTGTCCATT AAATGTCAGC TCTCAAGTAA ATTGATGTAA -2011
AATTTTTGTA TAGAAACTA TTTCATATTA TTTGCACTTG ATGTTTAATT ACATTTTAAA TGTTTTGTTT -1941
GTTTCATTTT GTTTTGTTTT TGAGACAGAG TCTTGCTCTG TTGCCCACGC TGGAATGCAG TGGTGTGATC -1871
TTGACTCACT GCAACCTCTG CCTCCTGGGT TTAAGCGATT CTCCTGCCTC AGCTTCCTGA GTAGCTGGGA -1801
TTACAGGCGT GCACCACCAT GCCTGGCTAA TCTTTGTATT TTTAGTAGAG ATGGGGTTTC ACCATGTTGG -1731
CCAGGCTGGT CCCGAACTCC TGACCTCAAG CTATACACYT GCCTCAGCCT CCCAAAGTGC TGAATTACA -1661
GACATAAGCC ACTGTGCCCC GCCAAATGTT TTAAATAATT GTCACATATA TATACAAAAT AATTTATGTT -1591
ATAGGTAGGG ATCTTGTTAT ATTTTAACCT TCAAAGTATA TTCCTAAGCT TTTTATTTAT TTTTATTTT -1521
TTATTTATTG AGACAGTCTT GCTCTGTCTG CCAGGCTGGA GTGCAGTGGC GCAATCTCGA CTCACTGCAA -1451
ACTCTACCTC CTGGGTTCAA GCGATTCTCC TGCCCTCAGCC TCCTGAGTAG CTGGGATTAC AGGTGCGCAC -1381
CACCATGCCC AGCTAATTTT TGTATTTTAA GTAGAGACGG GGTTCACCA TATTGGCCAG AGCTGGTCTC -1311
AAACTCCTGA CCTCAGGTGA TCCATCCACC TCAGCCTCTC AAAGTGCTGG GATTATAGGT GTGAGCCACT -1241
GCGCCTGGCC TATTCCTAGC CTTTTATATA TAGACCTTTT TCTTTTTCAC ATTTTAAAGG AACTTTTATG -1171
TTAATCATG GAATATTTCA AACATACAGA AAAATCACAG AAAATAAATA ACAACCACTC ATTTATCTTC -1101
TCCCCAACC CATGTAATAA ATATTAAAAT ATTGTGTAA ATGCTAAATT TAACACATGC TAAAGGTTCC -1031
TGGCTGGATG TGGTGGCTCA CGCCTGTAAT CCCAGTACTT TGGGAGGAGG AGGTGGGAGG ATTGCTTGAG -961
TCCAGGAGCT CGAGACCAGC ATGGGCAACA TAGTCCGATC TCGTCTCTAC AAAAAACAAA AAAATTAGCT -891
GGGCATGGTG GTGTGCATCA GTAATCCCAG TGACTGGGAG GCTGAGGTGG GAGAATTGCT TGAGTCTGGG -821
-751

AATTTGAGGC TGCAGTGAGC CCTGATCATG CCACTGCATT CCAGCATGGG CGACATAGCA AAACCTGTCA
-681
AAAAAAAAA AAGTTTCCTC TCTGCCCCAC CATAGACAAC CACTCTTCTG ATTTCTATCT TCGTAGATGA
-611
ATTTTGCCCA TTCTCTTGTA TATGAAAGGA AP1 ACCAGACATT AGGCATTCTG GTGTCTGGTT TCTTTCACTT
-541
AAGATAAAAT TGAGTTAACC TGTATTGTTG TACAGAACTG CAGTTTGTTT TTTGTTATTT ATTGTAAAGA
-471
CAGGGTCTGG CTATGTTGCC TAGGCTGGTC TCGAACTGTT GGCCTCAAGC AATCCACCTG CCAAGCTCTG
-401
GGACCACAGG CATGAGCCAT GGCATCTGAT CKGTAGTTTG ATCTTATTTT TTGCTGAGTA GTAGCCCATG
-331
GCATGACTTT AP1 ATTATTTTGG GTGTCCATTC TCCTCTGGAG GGGCTCTGCT TTTTGAAACC ACACCCTGGC
-261
CTAGCTCCCC ETS TTCTCCCTGC CTCTCTGCAG GCTCACATCC ACATGCCAAG ACCTCTGCAG CCATTCTGCT
-191
TCCTGTCCCTT ETS CCACTCCTGT GGGACCTCAG AGAGCTACGG GGCTCCCTGG GTACCAACTG GCTCCTGAGG
-121
Sp1/Sp3 CCTGGGGGAG GGTGGTCTTC TGGGAGAAGG AAGCCAGGTC Sp1/Sp3 CCTGCAGGTT GTGGAGGGGG ACAGAATGAG
-51
GGTTTTTCCC CAGGATGTTG Sp1/Sp3 TTGGCCCCCTG CCCCCACTTC TGTCCATAA TTAACCACGC ETS CCCTCCTACC
20
CACTGTGCCC CTCTTCCTGC Sp1/Sp3 TGTGTGGAGG CCCTGAATCA TTATTTTAAC + TACCCCTGG GAGGGTGAGC
90
ACCTTCTGTG CTCTGTCCCC ETS AACCTCCAC TTCCCCTCAA CGCGCTGCTC AGGGATGACC TTGGGACTG
160
TGCTTTTCT ETS GAGTGGTAAG TGGGGCCAGG GTGCTGGGGA GAAGCTTGA GAGATTCTGA GGGGACTCCA
230
TCTGGGAGGG CAGGCTGGGG GCTGGTGGTC GGCTCCAACC ACTCTTATGA GGAGCTGAGG CAGGGGAGTG
300
CTTCATGTGC GAGTGGCCCC GAGTCAGTAG AGTGTGACCT GAATGAAGAG GGGCTCAGGG GCTGTGCTCA
370
GGTGGCGACT AAGCTACCTC TCCAGCTGGC TATGTTGTCC CAGGCTTCCC TGCTCCCACT CATGGAGTCC
440
CTGGTGTGGG TGACAGAGGT CTCCCCAGCC TCCCCCGGGA GTGGAAGGCC ACAGAAGCCA CCAGGGAGGG
510
GGAAAGGTTG GACATCACCT CCCTGGGCCT NNNNNTTCCC CCAAGTCCTG ACTGCACGTA GGGAAGAGGC
580

CCCCTGCTGA AAACCTGCATC AGAGTCACAT TCACGTGCCA TCAAAAATCA GGCTTGGCTG GGTGCGGTGG
 650
 CTCATGCTTA TAATCCCAGC ACTTTGGGAG GCCGAGATGG GCGTATCCCC TGAGGTCAGG AGTTTGTGAC
 720
 CAGCCTGGCC AACATGGTGA AACCCCATCT TTACCAAAAA TATAAAAATT AGCCGGGCAT GGTGGCGTGC
 790
 ACTTGTAATC CCAGCTACTT GGAAGCTGA GGCAAGAGAA TCGCTTGAAC CCAGGAGACG GAAGTTGCAG
 860
 TGAGCTGAGA TCGTGCCGTT GCACTCCAGC CTCAGCAACA GAGCGAGACT CCATCTCAA AAAAAAAAAA
 930
 AAAAAAGAA AAAAAAGAA AAGAGGCTGG GAGGTCCTAG GGATTGGGGC TTCTTTAACT CCCAGCCTCC
 1000
 CCGCCACCA AATATTCCTC AGTCTGCTTCTTATCATG GATTCAACT GATGTGGAG GACCTACGA
 1070
 TCTTCAGCA GATGCAGGC GGCTTTGGCTAGAGCGTGGT GCAGTTCGGT GGATCTCGGT AGGCCCCACT
 1140
 CACCCTCCTT CCCCACCTC CACTACATCA AGTCCTGTGG ATGGGTACAC GTGGGTACC CGAGGGAGGT
 1210
 GTCCTGGAGG AAGGCCAGCA GGGGTGAGAA GTCTTCCCTT GGCTCCTTG AGGCCCTGAC ATCAGCACCT
 1280
 ATTATTCTCA ATCCCAGGAA AGGCCACAAA ACTCTAGACA AGACCCTACC TTACCTCGGG AGGGAAGCCT
 1350
 TGAACCTGCC TCCCAGGCAG GGCCCACTC TTGGGGCCAG TATGGTCACA CAGGGCCAC ACTCATTAAC
 1420
 TTTGGAGTTT AATGTTCTGC CTTGACCTC TTGAAATTCC TGATTATTTT TATTTTATT TTTACTCCAG
 1490
 CTCTGTTACC CAGGCTGGAG TGCAGTGGT CAATCACAGC TTAGTGCAGC CTCAAACTCT CGGGCACAAG
 1560
 TGATCCTCTC ACCTCAGCCT CCTGAATAGC TGGGACCACA GGTGCATGCC ATCATGCCTG TTTTGTGTTT
 1630
 TGTTTTGTTT TACTTTTAC AGAGATGGAG TCTTGCTATG TTGTCCAGAC TGGCTGAACT CCTGGGCTCA
 1700
 AGCAATCCTC CTGCCTTGGC CTCCCAAAGT GCTGGGATTA CAGGTGTGAG CCACCCTGTC TTGCCAATTC
 1770
 TTAAAAATTT TATCTGTGCA TTTGTGTTTT GCAAGTAAAG AATGATGGCA GGGCTGGGCA CCATGGCTCA
 1840
 CGCCTATAAT CCAACSCCTT TGGGAGGCTG AGGCGGGCAG ATCATCTGAG GCCAGGAGTT TGAGACCAGT
 1910

L A S Y H G F N L D V E E P T
 I F Q E D A G G F G Q S V V Q F G G S R
 Inten 2
 (30191

1000
 1070
 1140
 1210
 1280
 1350
 1420
 1490
 1560
 1630
 1700
 1770
 1840
 1910

TTGGCCAACA CAGCAAAACC CCATCTCTAC TAAAAATGCA AAAAAAATTA GCCGGGCATG GTGGCAGGCA
 1980
 TCTGTAATCC CAGCTACTTG GGAGGCTGAG GCAGGAGAAT CGCTTGAACC TGGGAGGTGG AGGTTGCAGT
 2050
 GAGCCGAGAT CGTGCCACTT TACTCCAGCC TAGGTGACAG AGTGAGACTC CGTCAAAAAA AAAAAGTCAT
 2120
 GGGAGAAGGG AGATGTACTG GGGGTTTGA GCCTTAGCTC AGCAGCAGCC CCACCTCCCA CCGCCTCTG
 2190
 AAGGGTGGTG AAGGGGTATC AGCTGCTGGC TCCCCACCC ATGTGGGAGC AATGACCGCT GCTACCTTCC
 2260
 GCCCCTGGCA TGAGCTGGGT AAAGTCAGTT AGGGGCGCTC ACTCTGGGAG TACCCCGAGG GAGTGGGACA
 2330
 CTACATAGCA AATAAAAAAC GTCAGGACAG GTTGAGGAAA GAGAGCAGAA GAAAGGTAAG AGCCCCCAA
 2400
 CCCCAAGAGA CCCACAGTT TTATTTCAA TTGGGACCCA CAAATTATGA ACCTGCCCC ACTTCCAGGA
 2470
 GCTCACATTC TCCTGTCCCA GAGAGTTCAA GTCACAATGT GACACAGGTG TCACCAAGGT CTGGGGGGCG
 2540
 CAGGCAGGGA GAGAGCAGAC CCAGGAGGGT TCCATGGAGG AAGTGGTGCT GGCAGTGAGC CCCAGTGGAC
 2610
 AGGAAGGCTC AGTTGGTCAC GAGGAGCTAT AAGAGGTCAC CGAGCTCCAA CCGCGCACCC CTCTCCCTTC
 2680
 CTCATGTGAC TGGCAGTCTG GGGGGATGGA AGCAAGCACC AGGCACCAGG CTTTTGTTTT TCTTTATTTG
 2750
 GAAATGTGGT CAACTGAGGT GCACAAATCT GAAAGACCCA ATCTGATAAA GGATACACAT GTGCGTGCCT
 2820
 GGGTGAGCCC CACCTAGGTC AGCTGCTCCA GTGTCAAATC CCACAGGCAC AGGGCTGCCG TGGACCCCTT
 2890
 CTCATCACCC AACATCCCCA GAGAACCCTT GGTGAGACTT CTGTCACCAT CAGTTTTTTT GGCACATTT
 2960
 TAAAAAAGA ATACATTGGC TGAGTGCAGT GGCTTATGCC TATAATCCTA GAACTTTGGG AGGCTGAGGC
 3030
 GGGTGGATCA CCTAAGGTCA AGAGTTCAAG ACCAGCCTGA CCAATATGGT GAAACCCTGT CTCTACTAAA
 3100
 AAATACAAAA ATTAGCCTGG CGTGATGGCA GGTGCCTGTA ATCCCAGCTA GCTGGGTGAC TGAAATAGGA
 3170
 GATTTGCTTG AACCTGGGAG GTGGAGGTTG CAGTGAGCTG AGATCACGCC ATTGCACTCC AACCTGGGTG
 3240

ACAGAGTGAA ACTCTGTCTC AAAAAACATA TGGGTGATG GGTACACTA AAGTTTGTCT CATCGTTTGT
 3310
 ATCAGCAGGT TCCAACTGC TACCTCTCTA GCCAATGCTC AGATTTTCTT CACAAAGCCT TAGGCATCCC
 3380
 CTGAATCATG ATGCACAGGG ATTGTAGCTT TCTGTAAAGG AGCGGCACCT AGAAGGAACC CTCACATGGC
 3450
 CATTTAATGA AGCCTTGCTT GGCGCATTAA AATACACCAG TATCTGTCTG CTTTCTCAC AGACAGGAGA
 3520
 TTGTGGGTAG TGAGAAAACA TTTCCAAAT TAAAAACTT TCCCACTCAG GGAGTTTGC AAATAAACCC
 3590
 TTGACTCTAC ATAACTATAG ATATAGTTAT GGATCCTAGT AACTGCTTT ACATTGGCCA ATTGAAATTG
 3660
 CTTATACAAT ATTTAAATTG GTCCAATGAA TTACAGAATC AACTATTTGT TTTGAAAGCA CATGTCTTCA
 3730
 GGAAATTGTT CCAATTAAT TGAGATGATC TTATTTCTTG GGTGGTTCAA AATAATGGCA ACTCAGAAAC
 3800
 GCAATGTGCT TACCCATGAT TGGGAAATGC CATTTTGGTC TTAAATAGG TCTTTTTTTT TTTTTTTTTT
 3870
 TTTTTTTTTT GGTGAATGTT AAAAAGAAAT TTCTAAACAT AAATACACAC ATACGTACTT ATGCACACTC
 3940
 AAAACCAAAT AAACCCAGC ATGGCCCTG GGCATCTGTG AGTTACACTT GGGCCCTGAT TTCTGAATAT
 4010
 TCTGCCAAGT GGCAAATGCC AGGAATTTCC CCCACAGAGT CTCGCTTCCC CATGGAGGGA CACTTCCTCA
 4080
 CCCCCAAGTG CCCGCTGCTC CCACCCCTCC TGTGGCTGCA GTGACATGGC CATGGTTGTG TCTCCAGACT
 4150
 CTTGCTGGGA GCACCCCTGG AGTGTGTC GCACAACAG ACGGGACGGC TGTAAGACTG CGCAGCTGCC
 V V G A P L E V V A A N Q T G R L Y D C A A A
 4220
 ACCGGCATGT GCCAGCCCAT CCGCTGCAC AGTGAGTGAC CACCTGGGAA TTGGGCCCT CAACCTCTCT
 + G M C Q P I P L H I
 Intron 3
 4290
 GGACCCAAT GTGCCCCCGC TTAGCTTCCA GTCCAGACCT TCCCCGAAA TGAGTGTGTG CTGTGAGTGA
 4360
 GACCCCGCGT GTCTGCCCTT GCAGTCCGCC CTGAGCCCT GAACATGTCC TTGGGCTGA CCCTGGCAGC
 R P E A V N M S L G L T L A A
 4430
 CTCCACCAAC GGCTCCCGC TCTGTGAG TGAGTGTCTT GGGCCACGGG GGGGTGGGGT GGGGCGGGGG
 S T N G S R L L
 4500
 GTGTTGTTGG GCAGGAGGCT GGGGCTGGGA GTGAAGGAGG AGGGGCTGCT AGGGACTCCT GGCTCACAGG
 Intron 4
 4570

CTTCTGCCTC CAGGCGTGTG GCGCGACCT CTACAGAGTC TGTGGGGAGA ACTCATATC AAAGGGTICC
 = A C G P T L H R V C G E N S Y S K G S 4640 (1700)
 TGCCTCCTGC TGGGCTCGCG CTGGGAGATC ATCCAGACAG TCCCGAGGC CACGCCAGGT AGGTCCCTGG Intron
 C L L L G S R W E I I R T V P D A T P E 5
 CAGGCCATGG TTCCCTGTGG AGCACATGCT GGCAGTGGG GTGAGCAGGC GTGAGGCCTG TGTCTGGGCC (4207)
 4710
 CCTGTGCCCT CCCTGGAGGG CCGAGTGTGG CTAGGAGAGA AGCCAGGAGA AGAGGGTGGC TCAGGCAGGA
 4780
 GCCCTGCTGC TCCAGGGTAG AAGTTCTTTG CAGGGTTTTT CTTTATATTT TTTTCTTTTT AAGACAGGGT
 4850
 CCCTGCCAGG CACAGTGGCT CAGGCCTGTA ATTCCAGCAT TTTAGGAGGC TGAGGTGGGC GGGATCACCT
 4920
 GAGGTCAGGA GTTCGAGACC AGCCTGGCCA ATGTGGTGAA ACCCCTCTAC TAAAAATACA AAACAAAACA
 4990
 AAACAAAATA GCAGGATGTG GTGGTGTGCG CCTGTAATCC CAGCCACTCG GGTAGGCAGA GACAGAAGAA
 5060
 TCGCTTGAAC CCAGGAGGCG GAGGTTGCAG TGAGCTGAGA TTGTGCCATT GCACTCCAGC CTGGGTGACA
 5130
 AGAGCAAAAC TCCATCTCAA AAAAAAAAAA AAAACAAAAA ACAGAGTTTC TGTCAGGCTG CATGCACCAC
 5200
 CACACCCTGC TAATTTTTTT GAGACAGAGT CTGCTCTGT CGCCAGGCT GGAGTGCAGT GGTGCAATCA
 5270
 TAGCTCACTG CAGCCTCGAA CTCCTGGGCT CAAGTGATCC TCCTCCCTTA GCCTACTGAG TAGTTGGGAC
 5340
 TGCAGGTACA TGCATCACAC CTGGCTAATT AAAAAAATG TTTTGTAGA AATGGGGGTC TTGCTATGTT
 5410
 ACCCAGCCTG GTCTTGAAC CTGGGCTCA AGTAATCCTC TGCCACAGCC TCTCAAAGTG TTGGGATGAC
 5480
 AGGCATGAGT CTTGTGCCT GGCCTGAGGG ATGAAAGTTC TGATGGAGGC AGAGAGGAGC CCCACTGTGC
 5550
 GGGCTGTAGA GGGCACAGCA TCTCCAGTT GCCAACAGGT GCATGGCCAC TTCTTGAGTT TCAGAGGAAG
 5620
 GACCTTAGTG TGGTAAAGAA CGTGGTGAGG AAGATAAATC CATGAGGGAG GTGTTTCTTC TGGATGGTTC
 5690
 ACTGCTGAGC TTCCAGGATT CCCAAACTA ACTTTCCTCT CGAAGAGGAG CAAATGACAG GGCTGCGGAA
 5760
 AATGCGATGT GCAATTTTGT CAGTGCCCAT GTCTTCACA GAGAACAGGG CCTGGGGACA CCACCATGAC
 5830
 5900

ATCTCTCTGA GGGTTGGTCT GCATCATGGT GGTGCCAAG TTTGTTTTCC ATGGGCACCA GGCTTCATTC
 5970
 CCTTGAAGCT TCATTCCCTC AAAGCCATTC AGTTTCCTCA TTGGTAAAT AGAGCTCAAT AATCAGGGGG
 6040
 TTATGAAGGT GAAAGGGATT GAGGTGCATA AAGCACTTGG AACCTGCCT GGCACATAGT ATGTGATAGC
 6110
 CCCTCTGACC CATCTTCCAG CTGGGGACTG CATGCTGGGA CTGGGAGGAA GATACAGGCA AACTGTCTCA
 6180
 TCTGCCGTGT GAGAGGGAAT GCCAGGGGCC GCTCAGGGTG CTGACCGAGG GTGGGGCTTC AGACCAGAGA
 6250
 GGCCATGATG ACAGGCATGC TGGGCCTTTA GACAAAGGTG GAGCAGCAGC AGAAACATTA CCAGAGCAAA
 6320
 TGGTGAGGGT GGACTCTATG GAGGGGACCA AGGGAAGGGG GAAGGGACAT CCAGGGTTCT TGGGGGGACC
 6390
 GTGCCCAGCC TGAGATGTCT GTGAAGCTAG GTTAGGGAGG TGGCACTTAA AAACAAGGGG TAAATGTCTT
 6460
 CTCACAGCCA TCCGTGGAAC TCATGAGGTG GGATGCCTGA TGCAAATGGG ACTGGAGCAC AAAACTGGTG
 6530
 CAGGCAAGGG GGGTGTGGGT CCAAGTAGAA GGGACCAGGG TCCACTGAGG ATCACCTGTG TGCCAAGCAG
 6600
 TGCTGAATAC CTGGTATGAA TCACCTTATT GCATCCTCAC AACATCCTGG GTGGTGGGCA GGCCCATCTT
 6670
 CATTTTACAG ATATGAAAAC CAAGGTTTCTG ATAGATGAGT TCCATCGATA GCAAGAGGCA GAGCCCAGAG
 6740
 CTTGAGCCAT CCTTGCCTGA TTGGTGGGGT CCTTTTTTCAA AAGGATAAGT CCAGGCTTCT GCTAGTGGGA
 6810
 GACCAGGGGA TACAATAAAA AGACCAAGAA ACAGAAGAGA CATTGTGAGA GGATTTGCCA CAGACCTGGC
 6880
 CTGAGAGAGG ATGAGAGGGT GGTTCCTTGA CGCAGCTGAA AAAACAGGCA CCACTGCAAG ATGTTGGCTG
 6950
 CCCAGATGTG GGCAAAAAAC GGGGAGCTCC TGGGGGGATC TGCAGCCTGC CCCATGGATG TCAAGATTG
 7020
 CTGGTGATTG AAGAAGCAGG AAGGAAGTGA CCTTCTGTTT CTCCCCAGCA CCCTTGAAGC ACCAGTGGTT
 7090
 GAGCAAGTGG GGTAGGGGAG AGGAAAGAGG AAAAGGCATT TTTTTTTTCT GCAGTGGTGG GCAGGGGGCA
 7160
 GAAACCACAG CCCTGTGGTG TGGGCCTCAC ACCTTAGTGC TCTGGTGGCC TGATCTCCCA GTGCCCTGCG
 7230

GGCAGCACAG GATGTGGCTG CTGGTGGAGG TACCAACTGG GCCCTGAACA CAGGCCACAC ACCCCCCATG
7300
AGCCTGGGGA CAGCATGAAA AGTCTTATTT GTTCATGTGC ATATGATGTG CCCTCACGAT TGCAGAGTGA
7370
ACTCCACAAA CTCTGAGGTC ACTTGGGAAT GTTCTTTTTT TTTGAGACGG AGTCTCACTC TGTGCCCCAG
7440
GCTGGAGTGC AGTGGCACAA TCTTGGCTCA CTGCAGCCTC CACCTCCCAG GTTCAAGTGA TTCTCCTGCC
7510
TCAGCCCCCC AAATAGCTAG GATTACAGGC ACCGCCACCA TGCCGGGCTA ATTTTTTTGT ATTTTGTAGTA
7580
GAGATGGGGT TTCACCATGT TGGCCAGGCT GGTTTTGAAC TCCTGACCTC AAGTAATCCG CCCACCTCAG
7650
CGTCCCAAAG TGCTAGGATT ACAGGCGTGA GCCACCACTC CCAACTGGGA ATATTCTTGG GCACCGCACC
7720
CATGGGAGCA TGAAGGGTGG ATGCAATGCA ATCATAACAG AGGCCCAAGG TCAGCACTGG GGTGCTTGCC
7790
TGTCATCCCA GTGCTTTGGG AGGCCGAGGT GAGTGGATCG TTAGAGCCCA GGAGGTTGAG ACCAGCCTGG
7860
GCAACATGGC GAAACTCCGT CTCTACAAAA AGATACAAAA ATTAGCCAGG CAAGGTGGTG CACACCTGTA
7930
GTCCCAGCTA CTCAGGAGAC TGAGGTGGGA GAATTGCCTG AGCCTGGGGA GGTGAGGCT GCACTGACCT
8000
GTGATCACAC CACCACACTC CAGCCTGGGT GACAGTGAGA CTCTGCCTCA AAAAAACAAA AAATGAAAAA
8070
ACCAGAGGCC TCAGCCAATG CCTGGGGGGC TCAGAGTGCA GCTGGCCCTT CAGACGCTGA ACCAGTCATC
8140
GGTAAAGGTT TCCTCCAGGG GCAGGAGGTG TCCCAGTGGG CAACAGTTCC CCTCTGCCTA GCGTGATTCC
8210
TGGGAAGGGA CTCAGCTCAG AGCCAACTCC ACGTAGCTGG AAATAAGGAC CTCTGACCGA CTGGGGGTAG
8280
GGTGGGGTCT GGGGTGGATC CCTGCCCCAC CCCCACAGCA TCCCTACAGG CATATCCTAC AGGCCTCGAA
8350
GGTGCCTGGC ACGTGGTGAG AATGGTGCCA GCGGCTGACC CTGGCAGAGG GCCAGGACTT GTCTCCAGCA
8420
CCCATGTGCG TGTTGCTTTA TCCTTGCACT GATCCACGTT GGTAGCCACT GATATTACCT TCATTTTACA
8490
GATAGGGACA CTGAAGTCCA GAGAAGTTAA GTAATGTGCC TGAATTCACC AATTAGCAGG TGGCTGAGCT
8560

GGGGTTTAGC CCAGGCACAC TGGCTCCAGA ACACGCGCCC TGAACCACTT TGCTAAACAT TCGCCCTTGA

8630

TGCTTGTTGGC ACCCCTAGCA TCTGTGTTTA ATGAATATTT GTTGATTAAA TGGATGAGGA GCCCACCTGG

8700

GTCCTGTGTT GTCATCCCTC TCTTTCCAGG CCATGTGGGA GGAAGGGAGC AGGGGGCTGG GGTGGCAGAC

8770

TGGGGCCTCC TCCAAGGAGG GGTGCGAAAC TAGGTGGGGA TGCCAAGAAC AGCCCCCGGG CTCTGTTGAG

8840

CAGGAGCTGC AGGAGGGGGT TGGGCCCCCG CAGTGCATCT CCGATTCCCTC CCCATTCCCC CACAGAGTGT

8910

CCACATCAAG AGATGGACAT CGTCTTCTG ATTGAGGGGT CTGGAAGCAT TGAACAAAT GACTTTAAAC

P H Q E M D I V F L I D G S G S I D Q N D F N Q

8980

AGATCAAGCG CTTTGTCAA GCTGTCATCG GCCAGTTTGA GGGCACTCAC ACCCTGGTGA AGACTGGGCA

M K G F V Q A V M G R F E G T D T L

9050

CCTGGGGCTG GGGTTTGGGG GACGGGGGAG GCTGGCCTCG GGGAGGCATC CCGGGAGGGG TGGGGGCAGG

9120

CCAGTGAGCC GTGTGTGATG GGGCTGGGGT GGAGAATGAA GCTATGGTCC CAGCACAGGC CCAACTTGAG

9190

CCCTGACCTA GGAGGCCCTC TTGGCATTTA ATAATGTATC CAAAAGCTAC AGGAAATACA ATGTTTCTGC

9260

TGTTTAAAAA CATTGAAAGT GTTTAAAAAA TAATTTTGCT ATGGAATTTG ACTGACATAT TTTCTATGTA

9330

ACTAATGATT TCTTTTTATT ATTTTATTTT CCCATAACTA GTGCCTATGT ATGTGCAAAA AAACCCCACT

9400

GTTTTGTTTT TTAAACAGGG TCTTGTTCTG TCATCCAGGC TGCAGTGTGG GGGTGCAATC ATAGCTCACT

9470

GCAGACTTGA TCTCCAGGC TCAAGTGATC CTCTTTCCTC AGCCTCCTGA GTAGATGGGA CTACAGGTGC

9540

ATGCCACCAT GCCTGGCTAA TTTTAAAAAA TTTTATTGT AGAGATGGGG TCTTGTTATA TTGCCCCAACC

9610

TGGTCTCCAA CTCCTGGCTC AAACAACCCT CCCACCTTGG CCTCTCAAAG TGCTGGGATT ACAGGCATGA

9680

GTCACTACGC CCAGCCACAA ATTCTTGAGA AGGGAGGAAA TACACAAATT GATTTAATGT GTGATAAAAT

9750

TTTTAAAAAG CTAAGGGTAG CAAATATTGT GGTTGGCAAA GTTATTTTTA ATAAACTGTG AAGGAAATAT

9820

CATTTGGTTT AGATTTTCCA GTTTATATTT TGTATTTTGT GGCCAATGAA TTTTCTTCTC TGGGTTTCAG

9890

(1772)

(1410)

Intron 1
(1255)

TATATTATTT GTAGGGCTTC AAAACACATG GGAAATGGTT TGTAATCCA AAATAATTCC AAAATAAAGT

9960

TTATTAAAAC TGAAAACAAT ATGGCTTGGT GTGGTGGCTC ACACCTGTAA TCCCAGCACT TTGGGAGGCT

10030

NGAGGTGGGA GTATTGCTTG AGGCCAAGAG TTCGAGACCA GCCTGGGCAA CATAGTGAGA CCTTGTCTCT

10100

ACCAAAAACA AAACAAAACA AAAAACAAAG CCAGGCATGT GACGTGTGCC TGTAGTTCCA GCTACTTGGA

10170

GGCTGAGGCA GGAGGATCAC TTGAGGCCAG GAGTTTGAGA GACCCTGTCT CTACAAAAAA TTAAAATAAA

10240 (1922)

AACAATAGTA ACAGGCACTG AGCCCTGGGC CCTCCCCACT GGCCTTTGCA GTTTCACCTG ATGCAGTACT

F A L M Q Y

10310

CAACCTCCT GAAGATCCAC TTCACCTTCA CCAATTCCG GACGAGCCCG AGCCAGCAGA GCTGCTGGA

S N L L K I H F T F T Q F R T S P S Q Q S L V D

10380

TCCCATCGTC CAACTGAAAG GCTGACGTT CACGECACG GGCATCCTGA CAGTGTGTA AAGCAACCCC

P I V Q L K G L T F A A I I T V
GACCCCA... Intron 7 T G L

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled **MYELOID CELL PROMOTER AND CONSTRUCTS CONTAINING SAME**

the specification of which (check one)

 X is attached hereto.

 was filed on as United States Application Number or PCT International Application Number and was amended on (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date

I HEREBY CLAIM the benefit under Title 35, United States Code, §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number
		1/17/95	

I HEREBY APPOINT the following registered attorneys and agents of the law firm of FOLEY & LARDNER to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith:

HARRY C. ENGSTROM	Reg. No.	26,876
MARK A. KASSEL	Reg. No.	38,200
PETER J. MANGHERA	Reg. No.	40,080
BERNARD P. FRIEDRICHSEN	Prov. Reg. No.	P-44,689
RUSSELL J. BARRON	Reg. No.	29,512
STEPHEN A. BENT	Reg. No.	29,768

DAVID A. BLUMENTHAL	Reg. No.	26,257
JOHN C. COOPER	Reg. No.	26,416
JOHN J. FELDHAUS	Reg. No.	28,822
JACK L. LAHR	Reg. No.	19,621
PETER G. MACK	Reg. No.	26,001
BRIAN J. MCNAMARA	Reg. No.	32,789
SYBIL MELOY	Reg. No.	22,749
MICHAEL D. RECHTIN	Reg. No.	30,128
COLIN G. SANDERCOCK	Reg. No.	31,298
RICHARD L. SCHWAAB	Reg. No.	25,479
ARTHUR SCHWARTZ	Reg. No.	22,115

and I request that all correspondence be directed to:

Mark A. Kassel
 FOLEY & LARDNER
 P.O. Box 1497
 Madison, WI 53701-1497

Telephone: (608) 258-4272
 Facsimile: (608) 258-4258

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of first inventor	John D. Noti, Ph.D.
Residence	Athens, Pennsylvania
Citizenship	USA
Post Office Address	Box 359R Grimley Road, Athens, PA 18810
Inventor's signature	
Date	